Plasmacytoid Dendritic Cells Are Key Regulators of Immune Tolerance by Matta, Benjamin
 PLASMACYTOID DENDRITIC CELLS ARE KEY REGULATORS OF IMMUNE 
TOLERANCE 
 
 
 
 
 
 
 
 
by 
Benjamin Michael Matta 
B.S., The Pennsylvania State University, 2003 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
the School of Medicine in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2012 
 
 ii 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF MEDICINE 
 
 
 
 
This dissertation was presented 
by 
 
Benjamin Michael Matta 
 
 
 
It was defended on 
June 27, 2012 
and approved by 
Lawrence P. Kane, PhD, Associate Professor, Department of Immunology 
Adrian E. Morelli, MD, PhD, Associate Professor, Departments of Surgery and Immunology 
Anuradha Ray, PhD, Professor, Departments of Medicine and Immunology 
Fadi G. Lakkis, MD, Professor, Departments of Surgery and Immunology 
Marie C. DeFrances, MD, PhD, Associate Professor, Department of Cellular and Molecular 
Pathology 
 Dissertation Advisor: Angus W. Thomson, PhD, DSc, Distinguished Professor, Departments 
of Surgery and Immunology 
 
 
 iii 
Copyright © by Benjamin Michael Matta 
2012 
 iv 
 
Solid organ allograft rejection and many autoimmune disorders remain significant clinical 
problems despite the efficacy of current immunosuppressive (IS) drug treatments. Moreover, the 
side effects of global IS drugs that inhibit immune responses in a non-specific manner may leave 
the host susceptible to development of cancer and chronic infection. The need for antigen (Ag)-
specific treatments to reduce or eliminate the need for IS drugs is merited in these cases. 
 Dendritic cells (DC) are important Ag-presenting cells (APC) that mediate innate and 
adaptive immune responses, and have been widely investigated as potential cell-based 
therapeutics to bolster or supplant current IS drug treatments in transplantation and autoimmune 
diseases. Conventional (c)DC are the most potent APC, however, they can be modified and 
conditioned to instead modulate immune responses and promote Ag-specific tolerance. 
Plasmacytoid (p)DC, the primary cells that produce type I IFN and activate anti-viral immunity, 
are also recognized as holding significant tolerogenic potential. In this dissertation, I present 
novel data that support the tolerogenic function of pDC and highlight their inability to elicit 
strong immune responses in the absence of viral infection. pDC exhibit a more immature 
phenotype compared to cDC that correlates to their weak ability to stimulate T cells. Moreover, 
liver pDC are less mature compared to pDC in the spleen. They promote regulatory T cell 
function, suppress delayed-type hypersensitivity responses, and are critical for the spontaneous 
acceptance of murine liver allografts. My data show that the co-inhibitory molecule B7 homolog-
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1 (B7-H1) is important for the immune regulatory capacity of spleen and liver pDC, and that the 
cytokine IL-27 regulates critical inhibitory functions of liver pDC, including their expression of 
B7-H1 and their immune suppressive capacity in vitro and in vivo. 
 In summary, my data provide evidence that pDC are an attractive target for development 
of cell-based therapies and identify novel mechanisms utilized by pDC to regulate immune 
reactivity. I have described for the first time that donor pDC contribute to the spontaneous 
acceptance of murine liver allografts, a discovery that has important implications for 
development of future therapeutics to promote immune tolerance, especially in solid organ 
transplantation. 
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1.0  INTRODUCTION 
The immune system encompasses a complex network of tissues and cells that work in concert to 
protect the host from invading pathogens in addition to regulating unwanted responses against 
self-antigens (Ags) and harmless or inert Ags. Ag-presenting cells (APC) play a key role in 
maintaining the balance between immunity and tolerance, and direct immune responses against 
specific Ags. The most important APC is the dendritic cell (DC), a bone marrow (BM)-derived, 
professional APC that forms a critical link between the innate and adaptive immune systems. DC 
are highly specialized for the uptake, processing, and presentation of Ags to initiate adaptive 
immune responses, and also produce factors that direct innate immune responses, all in an effort 
to clear invading pathogens and resolve disease pathologies. At the same time, DC also possess 
distinct regulatory properties that control unwanted and unnecessary inflammatory responses 
against harmless foreign Ags and maintain tolerance to self. Plasmacytoid (p) DC comprise a 
highly specialized DC subset that is critical in directing anti-viral responses. In addition, pDC 
also exhibit potent immunoregulatory functions that make them an attractive therapeutic target 
for treatment strategies where the regulation of immune responses is warranted. 
1.1 DC LINEAGE DEVELOPMENT AND MURINE DC SUBSETS 
DC are a heterogenous population of BM-derived cells that arise from common progenitors and 
comprise multiple subsets [1, 2]. At the transcriptional level, PU.1 expression is required for the 
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development of all DC subsets [3], with an important function of driving the expression of 
multiple cytokine receptors that regulate DC development and differentiation (Figure 1.1). The 
hematopoietic growth factor FMS-like tyrosine kinase 3 (Flt3) ligand (L) is critical for DC 
differentiation [4]. This is demonstrated by the fact that mice lacking Flt3L have a severe 
deficiency in lymphoid-related tissue DC [5], and DC can be propagated from BM cultures in 
vitro [6-8] and mobilized and expanded in vivo through administration of recombinant Flt3L [9]. 
Additionally, macrophage (M) colony-stimulating factor (CSF) and granulocyte-macrophage 
(GM)-CSF can be used in vitro to propagate DC from BM [10] and in vivo to expand DC [ref], 
and both play significant roles in DC development and differentiation. 
In the steady state in the mouse, there are two major DC subsets arising from the same 
common DC progenitors [11]. Conventional (c)DC (CD11c+CD11b+B220-NK1.1-) are found 
both in the periphery and resident in lymphoid tissue and are specialized for Ag-uptake, 
processing, and presentation to CD4+ T cells on MHC class II molecules. cDC can be further 
sub-divided based on their phenotype and tissue localization, and include CD8α+ cDC which are 
reported to be efficient at cross-presentation of exogenous Ags on MHC class I [11]. The other 
main DC subset in the mouse is the plasmacytoid (p) DC (CD11clowCD11b-B220+CD8α-) subset. 
pDC are the primary cell type responsible for type I IFN production during viral infection [12, 
13] and are characterized by unique developmental programming, phenotype, and function. pDC 
will be characterized further in sections 1.4 and 1.5, and are the focus of the work presented in 
this dissertation. Commitment to either the cDC or pDC lineages is determined by the balance of 
transcription factor expression [14] and the timing at which each is predominantly expressed 
during development. The expression of these transcription factors may be delicately controlled 
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by the expression of microRNAs (miRNA; short, non-coding RNA sequences) that bind to 
mRNA and can regulate gene expression by promoting mRNA degradation and translation [15]. 
 
 
 
Figure 1.1 Growth factors and transcription factors that regulate DC differentiation. 
The developmental pathways from myeloid and lymphoid progenitors to precursor dendritic cells (pre-
DCs) in the BM and the peripheral diversification of DC subsets are shown. The approximate points at 
which key transcription factors are first required for DC development are indicated by vertical lines. 
Stages at which key growth factors have been determined to be essential are indicated. The development 
of both DCs and monocytes depends on high concentrations of PU.1, which regulates the expression of 
the cytokine receptors FMS-related tyrosine kinase 3 (FLT3), macrophage colony-stimulating factor 
receptor (M-CSFR) and granulocyte–macrophage colony-stimulating factor receptor (GM-CSFR). The 
development of CD8α+ and CD103+ DCs relies on the stepwise activity of interferon-regulatory factor 8 
(IRF8), inhibitor of DNA binding 2 (ID2), E4 promoter-binding protein 4 (E4BP4) and basic leucine 
zipper transcription factor, ATF-like 3 (BATF3), as well as on FLT3 signaling. CD11b+ DCs depend on a 
unique set of transcription factors, including RELB, IRF2, IRF4 and Ikaros, and to some extent on the 
cytokines M-CSF and GM-CSF. The plasmacytoid DC (pDC) lineage requires IRF8, a low level of PU.1 
and the absence of ID2. The differentiation of pDC from an immature precursor requires E2-2 and Ikaros, 
with induced loss of E2-2 converting pDC into cells that closely resemble CD8α+ conventional DCs. 
CDP, common DC progenitor; CLP, common lymphoid progenitor; CMP, common myeloid progenitor; 
FLT3L, FLT3 ligand; GFI1, growth factor independent 1; LMPP, lymphoid-primed multipotent 
progenitor; MDP, macrophage and DC progenitor. From Belz GT, and SL Nutt. 2012. Nat Rev Immunol. 
12:101-113. [1] 
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1.2 DC LINK INNATE AND ADAPTIVE IMMUNITY 
DC serve as a critical link between the innate and adaptive arms of the immune system. In the 
steady state, DC are highly specialized for internalization of Ags, and following processing, 
antigenic peptides are loaded onto MHC class II molecules and shuttled to the cell surface where 
stable Ag-MHC complexes are presented to CD4+ T cells. Inflammatory cytokines, damage 
associated molecular patterns (DAMPs) or danger signals, and pathogen associated molecular 
patterns (PAMPs) all serve to stimulate a maturation process that reduces DC capacity for Ag 
uptake and shifts their function towards Ag presentation and immune activation [16]. During this 
process, DC upregulate surface Ag-presentation and co-stimulatory molecules and produce 
cytokines that influence the activity of other cells and direct the immune response towards a 
resolution. 
1.2.1 DC provide 3 signals for optimal T cell activation 
Following an orchestrated processing sequence, antigenic peptides of a specific length are 
generated from acquired Ags, loaded onto MHC class II molecules, and shuttled to the cell 
surface for presentation to T cells. During this process, DC are being exposed to inflammatory 
stimuli and initiate signaling cascades that results in maturation into potent stimulators of the 
immune response. DC form an immunological synapse with T cells [17] and provide three 
critical signals which results in activation, T cell clonal expansion, and development of Ag-
specific memory. 
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1.2.1.1 Signal 1: Antigen capture, processing, and presentation 
Signal 1 provided by DC is presentation of Ag on MHC molecules whereby DC form long-term, 
stable Ag-MHC complexes on the cell surface to maximize interactions for Ag with the T cell 
receptor (TCR). DC express a multitude of receptors for recognition of foreign Ags and immune 
complexes, such as: Fc receptors [18]; Toll-like receptors (TLRs) [19]; Nucleotide 
Oligomerization Domain (NOD)-like receptors (NLRs) [20]; and a class of C-type lectins, 
including DEC-205/CD205 [21], DC-specific intercellular adhesion molecule-3-grabbing 
nonintegrin (DC-SIGN) [22], Langerin [23], and Dectin-1 [24]. pDC uniquely express sialic acid 
binding immunoglobulin-like lectin (Siglec)-H that plays a role in Ag-uptake, and will be 
discussed later in section 1.4.2.2. Once exogenous Ags are internalized, they enter the endo-
lysosomal pathway where they are degraded into short peptides and loaded onto MHC class II 
molecules, and Ag-MHC complexes are transported to the cell surface for presentation to CD4+ 
T cells. Small quantities of Ag can escape the endosomal pathway into the cytosol. Degradation 
of the Ag by the proteasome and trafficking to the endoplasmic reticulum (ER) results in further 
processing of the peptides for loading onto MHC class I molecules and shuttling to the surface 
for cross-presentation to CD8+ T cells [25, 26]. In some cases, small peptides may be loaded 
onto recycled MHC class I molecules within the endosome itself [27]. 
DC maturation involves down-regulation of the MHCII transactivator (CIITA) [28] which is 
responsible for regulation of MHC class II expression [29]. Mature cDC also downregulate 
MARCH1, a ubiquitin ligase that controls MHC class II ubiquitination and degradation, further 
stabilizing peptide:MHC class II complexes on their surface [30]. Interestingly, pDC 
differentially regulate MHC class II expression relative to cDC [31], and this may play a 
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significant role in their T cell stimulatory capacity. The impact of this unique characteristic of 
pDC and their role in Ag presentation will be discussed in more detail in section 1.4.5.1. 
1.2.1.2 Signal 2: Co-stimulation 
The upregulation of co-stimulatory molecules on DC provides signal 2 for T cell activation.  The 
B7 family of co-stimulatory molecules is probably the most important functionally for optimal T 
cell activation [32, 33]. B7-1 (CD80) and B7-2 (CD86) are co-stimulatory molecules with 
similar functions that bind to CD28 on T cells and drive T cell clonal expansion [34]. 
CD80/CD86 ligation of CD28 also drives T cell expression of CD40L/CD154, and subsequent 
interaction with CD40 on DC further increases CD80 and CD86 expression [35]. This is an 
important consequence of co-stimulation by DC, as it also supports their cytokine production, 
which provides signal 3 and drives T cell differentiation. 
1.2.1.3 Signal 3: Cytokine production and T cell polarization 
Production of cytokines by DC provides signal 3 for T cell activation and is important for several 
reasons. First, production of TNF-α can induce upregulation of integrins and adhesion molecules 
on T cells to enhance their migration to sites of inflammation. Second, depending on the type of 
pathogen/Ag that activates the DC, the cytokines being produced will direct polarization of T 
cells towards different helper T cell (Th) lineages. Recognition of bacterial degradation products, 
such as the TLR4 ligand bacterial lipopolysaccharide (LPS) induces high levels of IL-12 
production, which stimulates IFN-γ production by T cells and promotes T cell polarization 
towards Th1 responses. During allergic responses though, cytokines such as IL-4 can skew T 
cells towards a Th2 response, characterized by production of IL-4, IL-5, IL-13, and IL-10. 
Moreover, Th17 T cells that produce IL-17 can be stimulated by DC-derived TGF-beta, IL-23, 
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and IL-6 [36]. This subset is highly inflammatory, and induces strong recruitment of neutrophils 
[37, 38]. IL-6 can further promote the activity of effector T cells by antagonizing the 
development and function of Foxp3+ regulatory T cells (Treg) [39]. 
1.2.2 Breakdown of 3 signals can promote immune regulation 
The coordination and participation of all three signals from DC is necessary for sufficient and 
potent T cell activation, clonal expansion, and resolution of pathologic conditions. Deficiencies 
or alterations of one or more of these signals during T cell activation can lead to negative 
regulation of T cell function including anergy, activation-induced cell death, and generation of 
Treg. On the other hand, intentionally disrupting these same mechanisms used by DC during 
immune activation may allow for manipulation of DC to promote or restore tolerance and 
prevent or reverse unwanted immune responses, such as would be the case to prevent allograft 
rejection in transplantation, or reverse the detrimental self-reactivity in autoimmune diseases. 
1.3 DC AS REGULATORS OF IMMUNE TOLERANCE 
While DC are the most potent APC and are instrumental in driving innate and adaptive immune 
responses, their Ag-presenting capacity is a vital component in their reciprocal role as regulators 
of immune tolerance. Thus, DC participate in the maintenance of central and peripheral tolerance 
to self Ags, commensal bacteria and food Ags, and harmless or inert inhaled Ags, through 
multiple mechanisms involving negative regulation of T cell function. Significant effort has been 
put towards harnessing their immune regulatory properties through pharmacologic, biologic, and 
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genetic manipulation to generate tolerogenic DC to be used as a therapeutic alternative or 
supplement to current treatment strategies in transplantation and autoimmune diseases.  
1.3.1 DC maintain central and peripheral tolerance 
Although they are not the only APC involved in thymic selection, DC play an important role in 
shaping the T cell repertoire [40]. Thymic-resident DC can acquire self Ags (tissue-restricted 
Ags) that are shed from thymic epithelial cells (TEC) or released from TEC following apoptosis 
[41], and can acquire blood-borne Ags that enter the thymus through the circulation. DC can also 
migrate to the thymus carrying Ags obtained in the periphery for presentation and negative 
selection of CD4+ T cells [42, 43]. In cases where autoreactive T cells do escape thymic 
selection, steady-state DC in the periphery are capable of targeting these T cells and rendering 
them inactive [44]. These data suggest that DC have a unique role in negative selection of T cells 
in the thymus, and in the periphery they provide an additional level of control to prevent the 
potential deleterious pathology mediated by autoreactive T cells that escape thymic selection. 
Due to their enormous surface area and continuous exposure to various Ags, the airway and 
intestinal mucosal tissues must be carefully regulated to prevent unwanted immune responses 
against harmless inhaled and ingested Ags while maintaining immune reactivity towards 
potentially harmful Ags. A population of CD103+ (integrin αE) DC has been described as an 
important DC subset in maintaining and promoting immune tolerance in mucosal tissues [45-48]. 
CD103+ DC are believed to be important inducers of Treg that can inhibit unwanted effector T 
cell responses against inert Ags. 
In the steady state, airway DC are continuously sampling inhaled allergens and Ags. They 
then traffic to the draining lymph nodes (LNs), and in the absence of inflammation, DC remain 
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immature and induce effector T cell apoptosis and anergy, and can induce Treg [49] due to 
insufficient T cell co-stimulation and pro-inflammatory cytokine production. DC also play a 
pivotal role in the phenomenon known as oral tolerance [50], whereby orally administered or 
ingested Ags induces hyporesponsiveness upon subsequent exposure to that same Ag. 
Highlighting the role of DC in oral tolerance is the fact that Flt3L-mobilized mice that have 
significantly elevated numbers of DC exhibit enhanced development or oral tolerance [51]. Some 
of the mechanisms implicated in mucosal tolerance include, but are not limited to: a shift toward 
anti-inflammatory (IL-10) versus pro-inflammatory (IL-12) cytokine production [52]; DC 
production of retinoic acid [53, 54] which can limit effector and memory T cell expansion and 
promote Treg induction [55, 56]; DC production and activation of TGF-β [47], which is a critical 
factor for Treg development and function [57]; and deletion of Ag-specific T cells following Ag 
feeding [58]. 
These findings indicate that, in the absence of inflammatory stimuli (steady-state), DC can 
acquire Ag but remain immature, and thus, subsequent interactions with T cells leads to Ag-
specific hyporesponsiveness and/or induction of Treg. This critical function of DC serves to 
maintain tolerance to harmless self Ags, commensal bacteria, and inert inhaled allergens or 
ingested food Ags. The same properties and mechanisms of DC that maintain and promote 
tolerance in the steady-state have been the focus of manipulation of DC into what have been 
termed “tolerogenic DC”. 
1.3.2 Conditioning of DC by the local microenvironment: Non-lymphoid tissue DC 
DC resident in non-lymphoid tissues are reported to hold greater tolerance-promoting capacity 
compared to DC found in lymphoid tissues, and therefore, it has been realized that certain factors 
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in the tissue microenvironment may modulate DC function [59]. For example, the 
microenvironment of the liver contains factors such as prostaglandins (PGEs), retinoic acid, 
immunosuppressive cytokines (IL-10 and TGF-β) and enzymes (arginase I) that negatively 
regulate immune cell function, including DC [60]. Stellate cells [61, 62] and stromal cells [63] in 
the liver can act indirectly as regulatory cells by producing and secreting many of the above 
factors that condition DC towards a regulatory phenotype [60]. Maybe of more significance is 
the fact that the liver lies downstream of the gut and receives blood via the portal vein, which 
contains detectable levels of gut-derived bacterial degradation products (e.g., LPS; TLR ligands). 
This blood supply continuously bathes cells in the liver, including DC, and induces changes to 
their molecular framework that enhances their tolerogenic capacity [64]. Our group and others 
have worked to characterize hepatic DC [65-68] and dissect their phenotypic and functional 
differences they exhibit compared to DC in lymphoid tissues [69-73].  
Pulmonary stromal cells exhibit an ability similar to hepatic stromal cells to induce 
regulatory DC that are able to suppress T cell responses [74]. Additionally, TGF-β maintains 
Langerhans cells (skin-resident DC) in an immature state, as Langerhans cells from TGF-βR-
deficient mice show decreased MHC class II and co-stimulatory molecule expression [75]. These 
effects are not limited to cDC, however, as the regulatory factors (TGF-β, IL-10, and PGE2) 
found in the gut mucosa can suppress pDC production of type I IFN and IL-12 [76]. 
As mentioned earlier, CD103+ DC represent a subset of migratory DC found in mucosal 
tissues (gut, lung, and skin), and may represent an example of conditioning DC in the 
microenvironment of non-lymphoid tissues that ultimately promotes their regulatory function 
[77, 78]. CD103+ DC have been linked to the development of oral tolerance and induction of 
Treg [48, 79, 80], and are an important DC subset involved in regulatory immune responses. 
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1.3.3 Tolerogenic DC: Working towards antigen-specific immune regulation 
Research focused on harnessing the immunoregulatory properties of DC for therapeutic use has 
grown exponentially in recent years, and for several important reasons. Drug toxicities resulting 
from prolonged used of pharmacologic agents [81] can have detrimental effects on overall 
health, and can create new problems in addition to the condition being treated. Additionally, 
prolonged use of global immunosuppressants (IS) can lead to dysregulation of immune function, 
resulting in cancer [82, 83] and/or chronic viral infections [84]. Finally, in the case of 
transplantation, current IS regimens have been successful at preventing acute rejection episodes, 
but have done little to prevent chronic allograft rejection and associated pathologies, such as 
chronic allograft vasculopathy (CAV) [85]. The development of Ag- (or patient-) specific 
therapeutic intervention may reduce the need for or even supplant current pharmacologic 
treatments, therefore reducing the incidence of drug toxicity. Additionally, an Ag-specific 
treatment strategy that limits use of global IS would leave the rest of the immune system intact to 
combat bacterial and viral pathogens and may reduce the development of autoimmune disease 
and cancer. Finally, targeting DC to regulate Ag-specific immunity may promote long-term 
allograft survival by reducing the development of CAV and chronic allograft rejection in solid 
organ transplantation [86]. 
1.3.3.1 Characteristics of tolerogenic DC 
There are several key phenotypic and functional characteristics that have been used to describe 
tolerogenic DC (Figure 1.2) [87]. Typically, they express low levels of MHC class II and co-
stimulatory molecules (CD40, CD80, and CD86), while maintaining relatively high expression 
of the co-inhibitory molecules B7 homolog 1 (B7-H1; Programmed death ligand-1, PD-L1) 
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and/or B7-DC (PD-L2). Tolerogenic DC produce high levels of TGF-β and IL-10 and lower 
levels of IL-12p70, however, certain types of DC that are considered tolerogenic sustain high 
levels of IL-12p70 production [88]. 
 DC that are propagated or cultured in the presence of IS drugs, regulatory cytokines, or 
genetically engineered to be tolerogenic are typically resistant to maturation stimuli and maintain 
an immature phenotype that underlies their ability to negatively regulate effector T cells and 
promote Treg function [89]. Furthermore, the production of certain factors such as TGF-β or the 
tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) by tolerogenic DC can 
promote the induction, expansion, and function of Treg [48, 90]. A key feature of tolerogenic DC 
that is critical for their ability to function in vivo is a preserved or even enhanced ability to traffic 
to secondary lymphoid tissues following adoptive transfer [91]. Overall, tolerogenic DC are: 
phenotypically immature; resistant to maturation; exhibit poor effector T cell stimulatory 
capacity; promote effector T cell apoptosis; and are efficient at inducing and/or expanding Treg 
through multiple mechanisms. 
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Figure 1.2 Generation of tolerogenic DCs in vitro. 
 
Dendritic cells (DCs) that are generated in vitro from BM precursors (BMDC precursors) in rodents or 
blood monocytes in humans and non-human primates (NHP) have been rendered tolerogenic by 
controlling their culture conditions through exposure to cytokines, growth factors or pharmacological 
mediators, or by genetic engineering. DCs generated under such conditions can downregulate the 
outcome of the T-cell response by a single predominant function or, more frequently, by a combination of 
complementary mechanisms. CCR7, CC-chemokine receptor 7; CTLA4–Ig, cytotoxic T-lymphocyte 
antigen 4–immunoglobulin fusion protein; GM-CSF, granulocyte/macrophage colony-stimulating factor; 
HO1, haem oxygenase-1; IDO, indoleamine 2,3-dioxygenase; IB, inhibitor of NF-κB; IL, interleukin; 
ILT, immunoglobulin-like transcript; NF-κB, nuclear factor-κB; ODN, oligodeoxynucleotide; PDL1, 
programmed cell death ligand 1; PGE2, prostaglandin E2; TGF1, transforming growth factor-1; TNFR, 
tumour-necrosis factor receptor; VEGF, vascular endothelial growth factor. From Morelli, AE and AW 
Thomson. 2007. Nat Rev Immunol. 7:610-621. [87] 
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1.3.3.2 Generation of tolerogenic DC 
The natural ability of DC to promote and maintain tolerance to self Ags and the conditioning of 
DC within certain tissue microenvironments have provided cues for the generation of tolerogenic 
DC in vitro for therapeutic purposes, especially in the fields of autoimmunity and 
transplantation. The over-arching goal of these efforts is to generate DC that have many of the 
characteristics described above in section 1.3.2.1 and shown in Figure 1.2.  
Cytokine-conditioned tolerogenic DC 
Early studies focused on the regulatory properties of IL-10 and its ability to downregulate the 
stimulatory capacity of APC (macrophages and monocytes). This included negative regulation of 
MHC class II [92] and co-stimulatory molecule expression [93], as well as inhibition of pro-
inflammatory cytokine secretion [94, 95], leading to regulation of T cell responses [96]. 
Eventually this work shifted to DC, as IL-10-conditioned DC were identified as tolerance-
promoting cells [97]. IL-10-conditioned DC have potent immune regulatory functions that 
includes an enhanced ability to negatively regulate effector T cells and induction and promotion 
of Treg function [98-100]. TGF-β is another cytokine known to modulate DC function [101, 
102]. Interestingly, when IL-10 and TGF-β are combined to generate what has been termed 
“alternatively-activated” dendritic cells, they acquire potent immunosuppressive function [103-
105]. 
Exposure to other cytokines has been shown to enhance the tolerogenic properties of DC. 
Human monocyte-derived DC conditioned in IL-27 upregulate the expression of B7-H1 and fail 
to effectively stimulate T cell proliferation and cytokine production [106]. Moreover, in a model 
of insulin-dependent autoimmune diabetes mellitus, mice that were given DC exposed to IFN-γ 
were protected from disease onset [107]. 
 15 
Pharmacologic manipulation of DC to promote tolerance 
The use of IS to inhibit immune responses in transplantation and autoimmunity led to 
investigation into the effects of these drugs on individual components of the immune system to 
determine their mechanisms of action. Although its use in the generation of tolerogenic DC 
began more recently than many other pharmacologic agents, rapamycin (RAPA)/sirolimus has 
garnered significant attention for its ability to condition DC to favor their tolerance-promoting 
capacity [108, 109]. Early work by our lab uncovered important features of RAPA-DC: they 
exhibit reduced expression of co-stimulatory molecules; are resistant to common maturation 
stimuli; and exhibit a reduced T cell allostimulatory capacity compared to control DC [10]. 
RAPA-DC also show a profound ability to spare Treg over effector T cell function, and upon 
adoptive transfer, can prolong experimental cardiac [110, 111], vascularized skin [112], and 
composite tissue allograft [113] survival. 
In addition to RAPA, there has been extensive study of the influence of other IS drugs and 
pharmacologic agents on DC phenotype and function, and overall the effects are similar, despite 
different mechanisms of action. Again, as described above, these pharmacologically-modified 
DC are characterized by low expression of co-stimulatory molecules, resistance to maturation 
stimuli (including reduced upregulation of co-stimulatory molecules and decreased IL-12 
production), preserved or upregulation of IL-10 production, decreased T cell stimulatory 
capacity, increased induction of T cell production of IL-10, and induction or expansion of Treg. 
Pharmacologic agents implicated in these findings include, but are not limited to: cyclosporine A 
(CsA) [114]; FK506/tacrolimus [115]; dexamethasone [116]; vitamin D3 [117, 118]; aspirin 
[119]; PGE2 [120]; mycophenolate mofetil (MMF) [121, 122]; and Sanglifehrin A (SFA) [123, 
124]. 
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There are many characteristics of cDC that make them an ideal candidate for therapeutic use 
in promoting tolerance, including: ease of propagating these cells in vitro; their propensity for 
acquisition, processing, and presentation of target Ags; the ability to influence their phenotype 
and function through pharmacologic, biologic, and genetic manipulation; the capacity to migrate 
to lymphoid tissues upon adoptive transfer; and their ability to regulate T cell responses and 
promote Treg function. Many of the studies on cDC and tolerance, however, have relied on in 
vitro or ex vivo manipulation to maintain cDC in an immature state and skew their functional 
properties in favor of immune regulation. To this end, there has been increasing investigation 
into whether pDC, based on their unique immunoregulatory properties which favor immune 
regulation and tolerance, even in the steady state and in the absence of manipulation, may have 
similar tolerance-promoting capacity. 
1.4 PLASMACYTOID DC: A SPECIALIZED DC SUBSET 
As mentioned earlier, pDC are one of the major DC subsets in the mouse. Their main function in 
the immune system is as the primary producers of type I IFNs during viral infection, and they 
effectively link innate and adaptive anti-viral responses. They display many unique 
characteristics that define their functional role in the immune system and distinguish them from 
other DC subsets. 
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1.4.1 pDC lineage development 
The properties that define pDC may be partially explained by their unique developmental 
programming compared with other DC subsets (Figure 1.1). pDC arise from the same common 
DC progenitors as cDC [125, 126], yet they express a genetic profile that more closely resembles 
lymphoid (T and B) cell development [127]. Murine pDC can be readily propagated from BM 
cultures using Flt3L [6, 128], whereas GM-CSF and IL-4 that are used to generate cDC in 
traditional BMDC cultures inhibit pDC development [7]. One study has also identified M-CSF as 
a growth factor able to drive pDC development from BM cultures in vitro and in vivo in Flt3L-
deficient mice [129]. 
pDC lineage commitment is controlled by expression of the transcription factor E2-2 [130], a 
member of the E protein family, which plays a crucial role in lymphoid cell development [131]. 
E2-2 regulates expression of several critical proteins expressed at high levels by pDC relative to 
cDC, including IFN-regulatory factor (IRF) 7 and 8 [131, 132], and the transcription factor Spi-B 
in human pDC [133], and may be the most important genetic determinant of pDC development. 
The balance and strength of E2-2 expression versus PU.1, which is critical for development of all 
DC subsets, has been reported to be critical for directing pDC versus cDC development [1, 14].  
1.4.2 Phenotypic characterization of pDC 
pDC are phenotypically distinct from cDC [134] and are characterized by expression of unique 
cell surface proteins. Human pDC are characterized by expression of blood DC Ag (BDCA)-
2/CD303 [135], immunoglobulin (Ig)-like transcript (ILT)7 [136], and leukocyte-associated Ig-
like receptor-1 (LAIR-1) [137]. They were initially described as a unique DC subset from human 
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monocyte-derived precursors that expressed high levels of the IL-3R and drove T cell 
differentiation towards a Th2 response, and thus, were termed DC2 [138, 139]. Around the same 
time, another group described a population of “plasmacytoid monocytes” [140] that was linked 
to a previously described population of high type I IFN-producing cells [141, 142], but had the 
ability to stimulate Th1 responses and promote anti-viral immunity.  
Shortly thereafter, a murine equivalent of these cells was identified as a CD11c+ DC subset 
capable of producing high quantities of type I IFN [143]. pDC in the mouse express lower levels 
of CD11c than cDC and are B220+Gr-1+(Ly-6C/+Ly-6G+) and CD123/IL-3R-CD11b-CD19- [143, 
144]. They are typically referred to as a B220+CD11clow/int population of cells, however, this 
classification does not exclusively define mouse pDC [145]. Thus, within the bulk CD11c+ DC 
pool, several pDC-specific markers have been identified recently and are described in detail 
below. 
1.4.2.1 PDCA-1/BST-2/CD317/Tetherin 
Plasmacytoid DC Ag (PDCA)-1 is probably the most widely recognized and commonly used 
marker for pDC. The overwhelming majority of studies on mouse pDC target this molecule for 
isolation of pDC by immunomagnetic bead isolation and for cell sorting [refs]. Anti-PDCA-1, 
and the previously described monoclonal Ab 120G8 [146], both recognize BM stromal cell Ag 
(BST)-2 [147]. In the naïve mouse, BST-2 is expressed exclusively on pDC, but is upregulated 
on multiple cells types following immune activation involving type I IFN [147]. BST-2 is also 
known as CD317/Tetherin [148], and may function to inhibit the spread of enveloped viruses by 
binding to them and retaining them on the surface of the cell as they replicate and are released, 
slowing the spread of infection. BST-2 may also be an important molecule for direct targeting of 
pDC in vivo for therapeutic enhancement of anti-viral and anti-tumor immunity [149]. 
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1.4.2.2 Siglec-H 
Sialic acid-binding Ig-like lectin (Siglec)-H, is a pDC-specific marker that plays a key role in 
regulating production of type I IFN [150]. Siglec-H functions as an endocytic receptor, and 
targeting Ags for delivery to pDC via Siglec-H offers therapeutic potential in stimulating [151] 
or regulating [152] immune responses. Siglec-H lacks a cytoplasmic tail, and as a result, 
associates with the intracellular adaptor protein, DNAX-activating protein (DAP) 12 [150]. Ab 
stimulation of Siglec-H blunts TLR9-mediated production of type I IFN, and DAP12-deficient 
mice exhibit elevated levels of type I IFN production, highlighting Siglec-H as an important 
molecule that regulates critical functions of pDC. 
1.4.2.3 LAG-3 
Lymphocyte activation gene (LAG)-3 is a CD4-like molecule [153] that is expressed by 
activated T and NK cells and is only exclusive for pDC within the DC compartment. Like CD4, 
it binds to MHC class II with high affinity and can down-regulate Ag-specific T cell stimulation 
[154]. LAG-3 is also expressed on Foxp3+ Treg [155, 156], and has been associated with their 
regulatory function. It can be cleaved from the cell surface, and soluble LAG-3 (sLAG-3) can be 
detected in normal mouse serum [157]. 
Interestingly, LAG-3 mRNA was detected in tissues where T and NK cells were not 
normally distributed [158] and sLAG-3 was detected in Rag1-/-γc-/- mice [157] which lack T, B, 
and NK cells, suggesting a significant level of LAG-3 expression by another cell type. Further 
analysis identified LAG-3 expression within the DC compartment, and specifically identified 
LAG-3 on B220+CD11cint cells that were PDCA-1+ [159]. An extensive study on the role of 
LAG-3 in the functional immunobiology of pDC has not been performed. However, the fact that 
pDC have the capacity to suppress cDC function [160] and pDC can secrete up to five times 
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more sLAG-3 than activated T cells [159], suggests this could possibly be an important, 
previously unreported mechanism through which pDC may be able to regulate MHC class II+ 
cell function. 
1.4.3 pDC localization and trafficking 
In the steady state, pDC can be found in the T cell areas of the spleen, LNs, and Peyer’s patches 
[146]. cDC, on the other hand, are found in greater numbers in the marginal zone surrounding 
the T and B cell areas. pDC localization following activation may be dependent upon the specific 
TLR that is activated [161], most likely due to the resultant chemokines that are produced. 
Activated pDC form clusters and co-localize in the T cell areas, and the kinetics of pDC 
migration and localization within lymphoid tissues appear to differ from those of cDC.  
 Although CCR7 mediates pDC migration to LN [162], they also have a unique ability to 
directly enter LN from the circulation via high-endothelial venules (HEVs) [163, 164]. Several 
receptor-ligand interactions have been reported to contribute to pDC transmigration across HEVs 
[165], including multiple integrins, selectins and intracellular adhesion molecules (ICAMs) 
[164]. Steady-state pDC express CXCR4, a receptor for CXCL12 which is expressed on the 
surface of HEVs and can promote transmigration into LNs [166]. Following activation, pDC 
become sensitive to additional ligands that direct migration to inflamed LNs, including the CCR7 
ligand CCL21, and CXCR3 ligands [167], the latter of which further enhance the response to 
CXCL12 [168]. These same interactions are thought to control the kinetics and localization of 
pDC migration in the spleen during inflammation [161]. 
 CCR9 has been identified as the receptor for thymus-expressed chemokine 
(TECK/CCL25) and directs T cell trafficking during thymic development and to the epithelium 
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of the small intestine [169-171]. Recently, a subpopulation of CCR9+ DC in the small intestine 
has been shown to co-express classical pDC markers (B220, PDCA1, Ly6C), secrete IFN-α, 
migrate to CCL25, and home to the small intestine upon adoptive transfer [172]. This same 
subpopulation of cells was also reported to transport peripheral Ags to the thymus, where they 
deleted Ag-specific thymocytes [43]. Expression of CCR9 may be a key marker for pDC that 
possess significant tolerogenic function, and will be discussed further in section 1.5.2.1 relating 
to central tolerance, and section 1.5.3.4 regarding pDC in the setting of transplantation. 
1.4.4 pDC, type I IFN, and anti-viral immunity 
pDC are the primary type I IFN-producing cells in humans and mice [141-143]. They express 
high levels of endosomal TLR 7, 8 and 9 that sense single-stranded viral RNA (ssRNA; TLR7 
and 8) and unmethylated, CpG-rich viral and bacterial ssDNA (TLR9) [173]. Upon recognition 
of these TLR ligands, pDC rapidly induce transcription of anti-viral genes leading to the 
secretion of large amounts of type I IFN (up to 10 pg/cell, which is nearly 1,000 times more than 
any other cell type) [142], as well as the pro-inflammatory cytokines IL-6 and TNF-α [174] and 
up-regulation of co-stimulatory molecules such as CD80 and CD86 (Figure 1.4) [175]. pDC 
production of type I IFN serves as a critical link between the innate and adaptive responses to 
viruses through inhibition of viral replication and activation of neutrophils [176], macrophages 
[177], NK cells [178, 179], T cells [180], B cells [181], and cDC [182, 183]. Although their 
unique ability to induce such potent anti-viral immune responses through type I IFN production 
suggests pDC might not be suited to promote tolerance, in the steady state or in the absence of 
type I IFN production, pDC are well-equipped to regulate immunity. 
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Figure 1.3 Activation pathway in plasmacytoid dendritic cells responding to nucleic acids. 
 
Resting plasmacytoid dendritic cells (pDCs) predominantly express Toll-like receptor 7 (TLR7) and 
TLR9, which reside in the endoplasmic reticulum (ER) in association with UNC93B and gp96. Following 
exposure to virus or nucleic acids, TLR7 and TLR9 relocate from the ER to the endosomes to engage 
with their RNA or DNA agonists. Conformational changes in the TLRs lead to the activation of MyD88 
(myeloid differentiation primary-response gene 88) and its further association with TRAF6 (tumour-
necrosis factor (TNF) receptor-associated factor 6), BTK (Bruton's tyrosine kinase) and IRAK4 
(interleukin-1-receptor-associated kinase 4). The MyD88–TRAF6–IRAK4 complex then activates IRF7 
(interferon-regulatory factor 7), TAK1 (transforming-growth-factor--activated kinase 1), nuclear factor-
kB (NF-kB) and IRF5 to propagate the downstream signals. Most importantly, IRF7 is activated through 
TRAF3, IRAK1, IKK (inhibitor of NF-B kinase ), osteopontin (OPN) and phosphoinositide 3-kinase 
(PI3K). Following ubiquitylation and phosphorylation, IRF7 translocates to the nucleus and initiates the 
transcription of type I interferons (such as IFN, IFN, IFN and IFN). TAK1 triggers the activation of NF-B 
and MAPKs (mitogen-activated protein kinases) and, together with IRF5, leads to the production of pro-
inflammatory cytokines and the expression of co-stimulatory molecules. IRF8, although not involved in 
the initial induction of IFN, magnifies IFN production through a feedback mechanism. By contrast, IRF4 
inhibits the function of IRF5 through direct competition. Autophagosomes, which are constitutively 
formed in pDCs via ATG5 (autophagy-related gene 5), are probably involved in transferring the nucleic-
acid agonists to endosomal TLRs for the production of IFNs. IL-6, interleukin-6; XBP1, X-box-binding 
protein 1. From Gilliet M, Cao W, and YJ Liu. 2008 Nat Rev Immunol. 8:594-606. [173] 
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1.5 TOLEROGENIC pDC: MEDIATORS OF IMMUNE REGULATION 
There are many properties of pDC that clearly define them as the primary type I IFN-producing 
cells during viral infection. Within hours of activation by a virus, nearly two-thirds of the genes 
being transcribed in pDC are related to type I IFN production and are IFN response genes [173]. 
They produce up to 1,000-fold more type I IFN than any other cell type which both activates and 
protects other cells from being infected. There are other characteristics of pDC, however, that 
limit their immunostimulatory capacity and make them an attractive therapeutic target to 
promote immune tolerance. 
1.5.1 Immune regulation by pDC via the 3 signals of T cell activation 
During initiation of the adaptive immune response, DC provide three critical signals to T cells 
that drives their expansion, differentiation, and function (section 1.2.1). Several unique 
characteristics of pDC regarding these three signals results in their ability to promote T cell 
hyporesponsiveness and regulatory function due to sub-optimal activation. 
1.5.1.1 Signal 1: Regulation of MHC class II expression 
Following activation and maturation, cDC are the most potent stimulators of Ag-specific T cell-
mediated immune responses. This is due in part, to downregulation of the MHC II ubiquitin E3 
ligase membrane-associated RING-CH1 (MARCH1) [30], resulting in formation of long-term, 
stable Ag:MHC II complexes on their surfaces following activation. pDC, in comparison, exhibit 
weaker T cell stimulatory capacity [73, 128, 184], which may be due to their failure to 
downregulate MARCH1 [31] following activation. Thus, Ag:MHC II complexes on pDC are 
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continuously ubiquitinated, internalized, and in a constant state of turnover. We tested this 
property of pDC by utilizing B6 CD4+ transgenic (tg) T cells that have a TCR specific for 
BALB/c MHC class II-derived peptide (Eα52-68) presented in the context of B6 MHC class II 
(I-Ab). B220+ pDC propagated from BM culture using Flt3L and pulsed with Eα52-68 peptide 
showed a poor ability to stimulate Ag-specific T cells, even if they were stimulated with CpG B 
(Figure 1.5). When peptide was instead added to pDC-T cell cultures, the extent of pDC-induced 
T cell proliferation was much greater when compared to pulsed pDC. These data are highlighted 
by the fact that unstimulated pDC in the presence of continuous Ag induced similar levels of T 
cell proliferation compared to peptide-pulsed pDC that were stimulated with CpG B. This unique 
feature of pDC most likely arose so that pDC could continuously sample viral Ags allowing 
them to constantly update the T cell repertoire against viruses. In a setting such as transplantation 
where graft-derived Ags are continuously present due to cell death and cell turnover, this 
characteristic of pDC could contribute to their ability to promote Ag-specific tolerance. 
Several studies have shown that low levels of Ag presentation to T cells can promote Treg 
development [185, 186]. It is reasonable to assume then, that rapid Ag:MHC II turnover by pDC 
could translate into presentation of low levels of Ag (i.e. weak TCR stimulation), consequently 
enhancing their ability to promote Treg induction and function. Induction and support of Treg 
function by pDC has been reported in several models [187-189], thus, this unique characteristic 
of pDC suggests a previously unexplored mechanism through which they may promote tolerance 
via Treg. In support of this, it has been shown that silencing of the critical DC developmental 
transcription factor PU.1 leads to reduced MHC class II expression [190]. During development 
(Figure 1.1), DC precursors downregulate PU.1 as they differentiate into pDC [1] (compared to 
cDC which maintain high PU.1 expression), suggesting that low expression of MHC class II is 
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regulated transcriptionally during pDC development and differentiation, and thus, the ability to 
regulate effector T cell activation and promote Treg function is an inherent property of pDC. 
 
 
 
 
Figure 1.4 T cell stimulatory capacity of pDC is increased upon continuous exposure to Ag. 
 
pDC were propagated from B6 BM using Flt3L in 10 d culture. pDC were isolated by B220 positive 
selection using immunomagnetic bead isolation. Cells were cultured for 18 h in the absence or presence 
of BALB/c MHC class II-derived peptide Eα52-68 and 100 ng/ml CpG B. Cells were collected, washed, 
counted, and cultured with CD4+ TEa tg T cells for 3 d. Unstimulated and CpG B-stimulated pDC that 
were not pulsed overnight received peptide in culture with T cells for the duration of the assay. 
Proliferation was quantified by radioisotope incorporation using a liquid scintillation counter. Statistical 
significance was calculated for the difference between Ea52-68 (Pulse; open circles) versus Ea52-68 
(Continuous; open squares), and Ea52-68/CpG B (Pulse; filled circles) versus Ea52-68/CpG B 
(Continuous; filled squares). ** p ≤ 0.01, *** p ≤ 0.001. 
 
1.5.1.2 Signal 2: CD86 versus B7-H1: Tipping the balance towards immune regulation 
Despite their ability to regulate immune responses, DC remain the most potent inducers of T 
cell-mediated immunity. An important component of their function is the expression of co-
stimulatory molecules that support T cell activation by providing signal 2. It is recognized, 
however, that the outcome of T cell responses is ultimately determined by the balance of co-
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stimulatory versus co-inhibitory molecules expressed by DC [191, 192]. To this end, there are 
two key factors that underscore the regulatory nature of pDC: first, they exhibit a low expression 
of co-stimulatory molecules; and second, they display relatively high expression of the co-
inhibitory molecule B7-H1 [128]. Further evaluation of the B7-H1:CD80 and B7-H1:CD86 
ratios shows that pDC express comparatively high ratios relative to cDC [69, 128]. To highlight 
the significance of this, we have noted that the B7-H1:CD86 ratio on pDC is significantly higher 
in tolerant pediatric liver transplant patients that were successfully weaned from IS compared to 
those on maintenance IS, and this high B7-H1:CD86 ratio correlates with an increased frequency 
of CD4+CD25hi Treg [193]. B7-H1 is a well-known negative regulator of T cell responses that 
has been implicated in an immune regulatory role [194] in many disease states and experimental 
models, and will be discussed in greater detail in section 3.2.3. 
1.5.1.3 Signal 3: Pro- vs. anti-inflammatory cytokine production 
In addition to production of type I IFNs, pDC also produce other cytokines that drive T cell 
differentiation and regulation. Upon recognition of various pathogens, pDC secrete IL-6 and 
TNF-α [195], IL-12 [196] and IL-10 [72]. Contributing to their weak T cell stimulatory capacity 
relative to cDC, pDC have been shown to produce less bioactive IL-12p70 compared to cDC 
[69]. Moreover, certain tissues such as the liver, may condition pDC to acquire a more 
tolerogenic phenotype relative to pDC in lymphoid tissues, and thus their cytokine production 
may be skewed in favor of immune regulation (e.g., liver pDC produce greater levels of IL-10 
and less IL-12 compared to pDC from the spleen) [72]. 
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1.5.2 Regulating immune responses: pDC in the steady state and pathologic conditions 
The unique properties and multitude of regulatory mechanisms inherent in pDC suggest they 
may be important in preventing unwanted immune responses in the maintenance of central and 
peripheral tolerance as described above in section 1.3.1. Moreover, their potent 
immunoregulatory function may be targeted for promotion of tolerance in the setting of 
transplantation and autoimmunity. In contrast, immunoregulation by pDC can have a negative 
impact on health and disease by suppressing desired immune responses, such as in the setting of 
cancer. 
1.5.2.1 Regulation of central tolerance: pDC impact T cell selection in the thymus 
Two recent reports suggest that, like thymic cDC, human thymic pDC can drive natural (n) Treg 
development.  Thus, Martin-Gayo et al [197] have shown that, following activation with CD40L 
and IL-3, mature thymic pDC efficiently promote the generation of CD4+CD25+Foxp3+ nTreg 
from autologous, positively-selected CD4+CD8+ thymocytes. The nTreg induced by pDC are 
better IL-10 producers and inferior TGF-β producers compared with those induced by thymic 
cDC, reflecting the ability of the two major DC subsets to induce distinct Treg repertoires, based 
on their distinct Ag-presenting capacities [31]. Studies by Hanabuchi et al [198] have further 
shown that activated human thymic medullary pDC express the thymic stromal lymphopoietin 
(TSLP) receptor and become responsive to TSLP, inducing the generation of Foxp3+ Treg from 
CD4+CD8-CD25- thymocytes. As in the former study, these Treg expressed more IL-10 but less 
TGF-β than those induced by TSLP-stimulated cDC. 
Although it was shown previously for cDC [42], it is now recognized that pDC can 
acquire Ag in the periphery and migrate to the thymus to participate in T cell selection [43]. 
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Their ability to traffic to the thymus was dependent on expression of the chemokine receptor 
CCR9, consistent with CCR9+ pDC being a tolerogenic population (see section 1.5.2.4). Taken 
together, these novel data suggest that pDC play a critical role in maintenance of central 
tolerance, through elimination of autoreactive (Ag-specific) T cells and selection of Treg that can 
preferentially secrete IL-10 in response to self Ag in the periphery. 
1.5.2.2 Autoimmunity: Regulation of unwanted immune reactivity against self-antigens 
Type-I IFN production by pDC has been implicated in the pathogenesis of autoimmune diseases, 
such as psoriasis, systemic lupus erythematosus (SLE), arthritis and type-1 diabetes [199]. Under 
normal, healthy conditions, the intracellular localization of TLR9, high concentration of 
extracellular DNases and low levels of unmethylated CpG motifs within mammalian DNA 
prevent pDC from sensing self DNA and secreting type-I IFN. However, several host factors can 
break down innate tolerance to self DNA, resulting in autoimmunity. For example, the anti-
microbial peptide LL37 and nuclear protein HMGB1, released by damaged and/or dying cells, 
bind self DNA fragments also released by dying cells to form aggregates that are protected from 
extracellular DNase degradation and delivered into early endosomes of pDC [200, 201]. 
Moreover, DNA-specific Abs bind self-DNA-LL37-HMGB1 complexes, increasing their 
translocation into TLR9-containing endosomes. The outcome of these responses is increased 
IFN-α production, activation of cDC, and promotion of autoreactive T cell responses.  
Although recent observations show that pDC are involved in the pathogenesis of 
experimental autoimmune encephalomyelitis (EAE), by promoting the induction of myelin 
oligodendrocyte glycoprotein (MOG)-specific Th17 cells [202], several reports suggest that 
tolerogenic pDC may regulate the severity of autoimmune disease (Table 1.1). Thus, mature 
pDC from rheumatoid arthritis patients with low disease activity express high levels of the 
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tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) and promote the 
differentiation of naïve CD4+CD25- T cells into IL-10-secreting Treg or T regulatory type-1 
(Tr1) cells [203]. Moreover, in vivo depletion of pDC exacerbates joint pathology and augments 
cell-mediated and humoral immunity to type II collagen in experimental arthritis [204], and 
enhances disease pathology in a model of EAE [205]. The regulatory role of pDC in EAE was 
dependent on suppression of IL-17- and IFN-γ-producing T cells through production of IDO. In 
an independent study, mice lacking MHC class II on pDC also show enhanced EAE severity due 
to lack of Ag presentation by pDC in LN and failure to induce myelin-Ag-specific Treg [206]. In 
support of these observations, targeting myelin Ags to pDC via Siglec-H led to inhibition of T 
cell-mediated development of EAE [152].  
In a murine model of lupus nephritis, low dose peptide therapy induces TGF-β production by 
pDC, expansion of autoAg-specific Treg and reduction of kidney-infiltrating inflammatory Th17 
cells [185]. Moreover, a protective effect of pDC against TCR transgenic T cell-induced type-1 
diabetes (T1D) in NOD mice has been demonstrated [207]. It has also been shown in both viral-
induced and spontaneous models of T1D that pDC in the pancreatic LN can be induced to 
produce TGF-β, which contributes to the conversion of islet-specific effector CD4+ T cells into 
Foxp3+ Treg that can prevent the development of T1D [208]. Thus, pDC appear to play 
important roles in regulation of several experimental autoimmune disease states and may serve 
as potential targets for restoration of tolerance to self Ags. 
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Table 1.1 pDC and the regulation of autoimmunity. 
 
1.5.2.3 Mucosal tolerance: pDC regulate immunity in gut and airway mucosa 
DC play an important role in maintaining tolerance to harmless inhaled or ingested Ags in 
mucosal tissues. Thus, several reports have recently implicated pDC in the induction and 
regulation of oral tolerance. The liver is a site of presentation of ingested Ags, and liver pDC 
appear to rapidly induce anergy or deletion of Ag-specific T cells via a CD4+ T cell-independent 
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mechanism. Goubier et al [209] have shown that pDC prevent fed Ag-induced T cell priming and 
are responsible for systemic tolerance to CD4+ and CD8+ T cell-mediated delayed-type 
hypersensitivity (DTH) responses induced by Ag feeding. Depletion of pDC in vivo prevents the 
induction of tolerance by Ag feeding, and transfer of oral Ag-loaded liver pDC to naive recipient 
mice induces Ag-specific suppression of CD4+ and CD8+ T cell responses. The anatomical and 
immunological location of the induction of oral tolerance likely occurs in the mesenteric LN, 
Peyer’s Patches, and liver, however, the presence of significant numbers of pDC in the tonsils 
that can induce and co-localize with Foxp3+ Treg [210] suggests they may act very early on 
during induction of oral tolerance. These data demonstrate that oral tolerance relies on Ag 
presentation by pDC to T cells, and suggest that pDC could represent a key therapeutic target for 
intestinal and systemic inflammatory diseases.  
It has also been shown that systemic depletion of pDC during inhalation of inert Ag leads to 
classic features of asthma: IgE sensitization, airway eosinophilia, goblet cell hyperplasia, and 
Th2 cytokine production [211]. Adoptive transfer of pDC prior to sensitization abrogates this 
effect, likely by inhibiting the generation of effector T cells induced by Ag-presenting cDC. In a 
model of Chlamydia pneumonia infection, pDC depletion during airway challenge allowed Ag 
sensitization to occur leading to asthma [212], suggesting that pDC play an important role to 
suppress asthma development as a result of pulmonary infection. In another model of airway 
tolerance induction, DC recovered from tolerized mice were dominated by B220+CD11c+Gr-
1+CD11b-MHC class IIlow cells that were poor T cell stimulators in MLR [213]. Together, the 
foregoing observations show that pDC can protect against unwanted inflammatory responses to 
harmless Ags and play a significant role in the development of tolerance at mucosal tissues. 
 32 
1.5.2.4 Transplantation tolerance 
Although the concept that pDC have potential to promote transplant tolerance has emerged in 
recent years [188, 214-216], the role of pDC in experimental transplant tolerance remains poorly 
characterized. Reports of the influence of pDC on transplant outcome are summarized in Table 
1.2. Two of the first reports to highlight the importance of pDC in alloimmune tolerance 
identified these cells as a critical and necessary component of a population of facilitating cells 
(FC) in BM that could promote hematopoietic stem cell engraftment [217] and induce Ag-
specific Treg in vivo [218]. More recently, this population of FC was shown to facilitate human 
kidney allograft tolerance with no incidence of GVH disease [219]. Adoptive transfer of donor-
derived pre-pDC suppresses GVH disease through IDO-dependent promotion of Treg function 
[220]. This may be an important mechanism through which pDC are able to promote allograft 
tolerance that is not dependent on donor Ag specificity. Highlighting this point, pDC propagated 
from donor strain, recipient strain, and even third-party BM using Flt3L could prolong murine 
cardiac allograft survival [215]. Another potential mechanism for this phenomenon is the 
induction of IL-10-producing T cells by pDC via ICOS:ICOSL (B7RP-1) interaction [221, 222]. 
Flt3L-mobilized splenic pDC of donor origin significantly prolong experimental cardiac 
allograft survival in the absence of IS or in combination with anti-CD154 (CD40L) mAb therapy 
[223]. Studies suggest, however, that recipient DC/APC may be more important in chronic 
rejection (and thus, more appropriate targets for therapeutic intervention), since donor DC have a 
finite life span in the recipient and are not replenished. In an experimental model of cardiac 
allograft tolerance induced by donor-specific transfusion and anti-CD154 mAb, recipient PDCA-
1+ pDC acquired donor MHC II-derived alloAg from the graft and migrated to LN (but not 
spleen), where they induced alloAg-specific CD4+Foxp3+ Treg necessary for tolerance induction 
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[188]. Depletion of pDC or prevention of pDC homing to LN inhibited Treg development and 
tolerance induction. Moreover, in CCR7-deficient mice that almost completely lack pDC in the 
LN, adoptive transfer of syngeneic pDC (but not cDC) restores cardiac allograft tolerance 
induced by DST and anti-CD40L/MR1 [224]. Interestingly, in a rat model of cardiac allograft 
tolerance induced by CD40Ig, pDC accumulated in the graft and the spleen, but not LN, and 
induced CD8+ Treg [225]. Regulation of alloreactive CD4+ T cells by pDC occurred either 
directly, through an IDO-dependent mechanism, or indirectly through CD8+ Treg, in a contact-
dependent manner. Similar results were observed for human pDC, as they induced a population 
of CD8+ Treg in an IDO-dependent manner that could suppress alloreactive T cells [226]. 
We have reported that analysis of peripheral blood DC, especially pDC, in liver transplant 
patients can be a helpful immune monitoring tool. Consistent with the more tolerogenic 
properties of pDC, higher incidences of circulating pDC relative to cDC are found in 
operationally tolerant pediatric liver allograft recipients, and in patients on low dose IS therapy 
undergoing prospective drug weaning, compared with patients on maintenance IS [227]. In 
addition, high PD-L1:CD86 ratios on pDC correlate with elevated CD4+CD25hiFoxp3+ Treg in 
tolerant patients [193], consistent with evidence that the balance between expression of 
inhibitory PD-L1 and co-stimulatory B7-1 (CD80)/B7-2 (CD86) ligands regulates the outcome 
of their interaction with T cells [191, 192]. Further emphasizing their importance, a lower ratio 
of pDC to cDC was associated with rejection in pediatric small bowel transplant recipients, 
suggesting that greater frequencies of pDC following transplant are critical for graft survival 
[228]. 
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Table 1.2 pDC and transplantation tolerance. 
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As mentioned earlier, CCR9 is a chemokine receptor expressed by pDC that directs their 
migration to the thymus and small intestine [172]. CCR9+ pDC express very low levels of Ag-
presenting (MHC II) and co-stimulatory molecules, a phenotype associated with DC immaturity 
or tolerogenicity [229]. When LN B220+CD11c+ DC were sorted based on CCR9 expression, 
pulsed with OVA and cultured with CD4+ T cells, the CCR9+ pDC failed to induce CD4+ T cell 
proliferation in vitro and failed to prime T cells in vivo, suggesting that these OVA-loaded pDC 
could promote Ag-specific T cell tolerance [229]. The potent tolerogenic potential of CCR9+ 
pDC is evidenced by their capacity to suppress acute graft-versus-host (GVH) disease when co-
transferred into lethally-irradiated recipients with allogeneic CD4+CD25- effector T cells [229]. 
One mechanism to account for these observations is an enhanced ability of CCR9+ pDC to 
induce highly suppressive Foxp3+ (CD4+CD25+) Treg and to inhibit the outgrowth of 
inflammatory IL-17-producing T cells [229]. Further investigation has revealed that 
B220+CCR9- cells are precursors of cDC, suggesting that, in conjunction with other classical 
pDC markers, CCR9 may be a key marker for terminally-differentiated pDC and does not 
necessarily indicate a pDC subpopulation [230]. Collectively, the evidence from experimental 
and clinical studies suggests that pDC have potent regulatory capacity in transplantation, 
including multiple mechanisms that are independent of donor Ag, and clearly support a role for 
pDC in promoting transplantation tolerance. 
1.5.2.5 Immune regulation in cancer 
Due to their ability to secrete high levels of type-I IFN and TNF-α, pDC would appear to have 
the potential to promote anti-tumor immunity through activation of NK cells and CD8+ T cells 
with potent cytolytic function. On the contrary however, pDC may regulate anti-tumor immunity 
and support immune evasion and tumor escape (Figure 1.6). Tumor-infiltrating pDC are 
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associated with poor prognosis [231], and are recruited into the tumor microenvironment (Figure 
1.6A) via several receptor:ligand interactions, including CCL20:CCR6, stromal cell-derived 
factor (SDF)-1/CXCL12:CXCR4, and very late Ag (VLA)-5:vascular cell adhesion molecule 
(VCAM)-1 interactions [232, 233]. pDC exposed to the tumor microenvironment are protected 
from tumor macrophage IL-10-induced apoptosis; they exhibit reduced IFN-α production upon 
TLR9 stimulation and can induce IL-10-producing CD4+ and CD8+ Treg [234-236]. This 
suggests that anti-tumor immune responses can be regulated through both modulation of pDC 
function by the tumor, and by limiting anti-tumor cytolytic activity through induction of 
regulatory CD4+ and CD8+ T cells. 
In addition to intratumoral immune regulation, pDC also exhibit immunoregulatory 
properties in tumor-draining LN (TDLN) (Figure 1.6B). A subpopulation of CD19+ pDC in 
TDLNs produces high levels of IDO [237]. Production of IDO by pDC has been linked directly 
to activation of naturally-occurring Foxp3+ Treg through modulation of the general control non-
depressive kinase 2 (GCN2) pathway, which leads to inhibition of protein synthesis and Treg 
activation [187]. IDO-activated Treg can suppress effector T cell responses directly, or 
indirectly, via the PD-L1:PD-1 pathway [187]. IDO plays a dual regulatory role by preventing 
conversion of these Treg into pro-inflammatory Th17 cells through autocrine inhibition of IL-6 
production via upregulation of GCN2 in pDC [238]. IDO has also been reported to inhibit 
production of IFN-α, which may limit their ability to activate innate and adaptive anti-tumor 
immunity [239]. In relation to other tolerogenic pDC populations already described, it would be 
of interest to determine if the reported CD19+ IDO-producing subpopulation of pDC in TDLN 
corresponds to the tolerogenic CCR9+ pDC reported to induce Foxp3+ Treg, inhibit Th17 
development and suppress GVH disease. 
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Figure 1.5 pDC regulate anti-tumor immunity and can promote tumor escape. 
A, pDC are recruited into the tumor microenvironment via multiple receptor–ligand interactions. 
Interaction of stromal cell-derived factor-1/ CXCL12 with CXCR4 on pDC can upregulate very late Ag-5 
for transendothelial migration via vascular cell adhesion molecule-1 and can protect pDC from IL-10-
induced apoptosis. CCL20 binding to CCR6 on pDC can recruit pDC to the tumor site. Factors produced 
within the tumor microenvironment can modulate IFN-α production via TLR9 stimulation. pDC cultured 
with tumor cells can induce IL-10 production by CD41 T cells and CD81 Treg. B, CD191 pDC in TDLN 
produce high levels of IDO, which can activate mature Treg via activation of the GCN2 pathway of 
protein synthesis inhibition. Activated Treg can then activate other DC, leading to upregulation of PD-L1, 
which suppresses anti-tumor T-cell responses. pDC-produced IDO and activated Treg can also convert 
naïve T cells into new Treg. IDO acts in an autocrine manner to suppress pDC production of IL-6, which 
prevents the conversion of Treg into IL-17-producing Th17 pro-inflammatory cells. IDO also 
downregulates IFN-α production by pDC. From Matta BM, Castellaneta AC, and AW Thomson. 2009. 
Eur J Immunol. 40:2667-2676. [240] 
 
1.5.2.6 Conditioning pDC for tolerance 
Although steady-state pDC exhibit many features of classical tolerogenic DC (Figure 1.2 and 
section 1.3.2.1), studies have investigated the effects of in vitro and ex vivo manipulation of pDC 
using pharmacologic and biologic agents. Human pDC treated with tacrolimus/FK506 prior to 
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TLR9 stimulation failed to upregulate co-stimulatory molecules and HLA-DR to the same extent 
as untreated controls, and showed impaired production of TNF-α [241]. The PGE2 analog 
iloprost showed similar effects on pDC through suppression of TNF-α and IFN-α production 
following stimulation with CpG [242], while enhancing their regulatory potential through 
upregulation of IL-10 production. PGE2-treated human pDC secreted less IFN-α and skewed T 
cell differentiation towards Th2 cytokine production [243], highlighting the potential for PGE2 
in targeting pDC to regulate Th1-mediated pathologies. In a recent study, cDC that were cultured 
with T cells that constitutively secreted high amounts of TGF-β acquired a “plasmacytoid-like” 
phenotype, and upregulated secretion of the immunoregulatory cytokine IL-27 [244]. In 
correlation with these findings, pDC exposed to TGF-β exhibited enhanced regulatory function, 
including elevated expression of IL-27, as well as a greater capacity for induction of Foxp3+ 
Treg [245]. Together, these data suggest that the inflammatory and regulatory functions of pDC 
may be manipulated for therapeutic purposes. 
1.6 SPECIFIC AIMS 
1.6.1 Specific Aim I (Chapter 3): To evaluate the contribution of B7-H1 to the immune 
regulatory capacity of splenic pDC 
The development of cell-based therapies for translation to clinical use has been studied 
extensively, and due to their ability to deliver Ag-specific signals, DC have garnered much of 
this attention. Recent data have highlighted the immune regulatory capacity of pDC (section 1.5) 
in the steady state and various disease pathologies, and suggest several mechanisms contributing 
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to their tolerogenic capacity. We demonstrate that splenic pDC are immature APC that exhibit a 
distinctly different cell-surface phenotype compared to splenic cDC, characterized by lower 
expression of Ag-presenting and co-stimulatory molecules which correlates with their weak T 
cell stimulatory capacity. We have also identified B7-H1 as a critical molecule that regulates the 
allostimulatory capacity of splenic pDC. The high expression of B7-H1 relative to co-stimulatory 
molecule expression (CD40, CD80, and CD86) limits the ability of splenic pDC to induce potent 
allogeneic T cell activation and proliferation, both in vitro and in vivo.  
1.6.2 Specific Aim II (Chapter 4): To investigate the mechanisms that contribute to the 
inherent tolerogenicity of liver pDC 
Liver pDC have been described as an important regulatory cell population able to suppress Ag-
specific DTH responses and that is critical for the development of oral tolerance. The 
mechanisms underlying these phenomena have not yet been reported. We show that the 
immunoregulatory cytokine IL-27 plays a critical regulatory role in the functional biology of 
liver pDC by promoting expression of B7-H1 which subsequently increases the incidence of 
CD4+ T cells expressing Foxp3 in MLR. The effects of IL-27 on liver compared to spleen pDC 
suggest the potential for unique signaling pathways in these cells which may be critical in 
regulating their tolerogenic capacity. Our data also show that IL-27 produced by liver pDC also 
restrains their ability to efficiently stimulate immune responses in vitro and in vivo. 
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1.6.3 Specific Aim III (Chapter 5): To determine the necessity for donor liver pDC in the 
spontaneous acceptance of fully MHC-mismatched murine liver allografts 
Highlighting the inherent tolerogenic nature of the liver, liver allografts are accepted 
spontaneously in the absence of IS treatment in fully MHC-mismatched strain combinations in 
rodents. Moreover, induction of tolerance in human liver allograft recipients typically requires 
less IS drug therapy compared to other solid organ allografts. We demonstrate for the first time 
that donor liver pDC are required for spontaneous and indefinite survival of mouse liver 
allografts. The weak ability of liver pDC to prime immune responses to alloAgs and high 
expression of important adhesion molecules suggests that as liver pDC migrate from the donor 
liver into recipient lymphoid tissues, they may be a critical component for the development of 
tolerance to liver allografts. 
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2.0  MATERIALS AND METHODS 
The following is a comprehensive description of all mice, reagents, experimental protocols, and 
statistical methods used to generate all of the data contained in this dissertation and publications 
resulting from work presented herein. 
2.1 MICE 
Six-week old C57BL/6 (B6; H2b), C3H/HeJ (C3H; H2k), and BALB/cByJ (BALB/c; H2d) mice 
were purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained in the specific 
pathogen-free Central Animal Facility of the University of Pittsburgh School of Medicine. Ebi3-/- 
mice (Ebi3tm1Rsb/J) purchased from Jackson and B7-H1-/- mice (breeding pairs kindly provided 
by Dr. Lieping Chen, Yale University, New Haven, CT), both on a B6 background, were bred 
and maintained at the University of Pittsburgh. Experiments were conducted under an 
Institutional Animal Care and Use Committee (IACUC)-approved protocol and in accordance 
with National Institutes of Health guidelines. The animals were fed a diet of Purina rodent chow 
(Ralston Purina, St. Louis, MO) and received tap water ad libitum. 
 42 
2.2 MEDIA AND REAGENTS 
The endogenous DC poietin recombinant human Flt3L (CHO cell-derived) was obtained from 
Amgen (Seattle, WA). Complete medium was composed of RPMI-1640 (BioWhittaker, 
Walkersville, MD) supplemented with 10% v/v fetal calf serum (Nalgene, Miami, FL), non-
essential amino acids, L-glutamine, sodium pyruvate, penicillin–streptomycin, and 2-
mercaptoethanol (all from Life Technologies, Gaithersburg, MD). The TLR9 ligand CpG type B 
oligodinucleotide (ODN) 1826, certified endotoxin free, was obtained from Invivogen (San 
Diego, CA). Low-endotoxin, azide free (LEAF) anti-B7-H1 neutralizing and LEAF Rat IgG2b 
isotype control Abs were purchased from BioLegend (San Diego, CA). Recombinant murine IL-
27 was purchased from eBioscience (San Diego, CA) and STAT3 Inhibitor VII and the STAT3 
inhibitor JSI-124/Cucurbitacin were purchased from Calbiochem/EMD Chemicals (Gibbstown, 
NJ). 120G8.04 mAb for in vivo depletion of pDC was purchased from IMGENEX (San Diego, 
CA). 
2.3 FLT3L-MOBILIZATION AND PURIFICATION OF DC SUBSETS 
pDC were purified as described [69]. Livers and spleens were harvested from mice administered 
Flt3L (10 μg/mouse/day; 10 days) and digested in collagenase (Sigma, St. Louis, MO). DC were 
enriched from total liver non-parenchymal cells or splenocytes by density gradient centrifugation 
using Histodenz (30% for liver, 16% for spleen) (Sigma). Liver and spleen cells were depleted of 
NK1.1+ cells to remove NK cells and NKDC [145] by incubation with biotin-conjugated NK1.1 
(BD Pharmingen, San Diego, CA) and anti-biotin magnetic microbeads (Miltenyi Biotec, 
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Auburn, CA), followed by depletion on an LS column (Miltenyi Biotec). pDC were positively 
selected using PDCA-1 magnetic microbeads (Miltenyi Biotec). Purity was consistently between 
93 and 97%, where the majority of contaminating cells were B220-CD11c+ cDC, with negligible 
contamination by B220+CD11c- B cells, as reported previously [69]. In some experiments, cDC 
were isolated from NK1.1-PDCA-1- cells by CD11c positive selection and stimulated with the 
TLR4 ligand LPS at 1 μg/ml. 
2.4 FLOW CYTOMETRIC ANALYSIS OF DC PHENOTYPE 
Liver and spleen DC were incubated in 5% v/v normal goat serum and FcγR-blocking Ab (anti-
CD16/32, BD Pharmingen) to block non-specific binding. For cell surface staining, cells were 
analyzed by 5-color analysis using FITC-, PE-, APC-/AlexaFluor647-, Pacific Blue-, and 
PE/Cy7-conjugated Abs. For phenotypic analysis of DC, surface expression of MHC class I (Kb) 
and II (I-Ab), CD40, CD80, CD86, B7-H1 (PD-L1), B7-DC (PD-L2), ICOSL (B7RP), Siglec-H, 
CCR9, LAG-3,  and WSX-1/IL-27Rα was quantified on a population of B220+CD11clow 
(PDCA-1-purified pDC) or B220-CD11c+ (CD11c-puified cDC) gated cells. . The gating strategy 
and expression of B220/CD45R, CD11c, and Siglec-H on purified PDCA-1+ pDC is shown in 
Figure 2.1. 
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2.5 INTRACELLULAR CYTOKINE AND FOXP3 STAINING 
Purified PDCA-1+ pDC were cultured for 18 h with 1 μg/ml CpG B ODN or 10-25 ng/ml IL-27 
and treated with Golgi Plug Protein Transport Inhibitor (1 μl/ml; BD PharMingen) for the final 5 
h. The cells were labeled for surface proteins as described above. For analysis of cytokine 
production, cells were fixed with 4% v/v paraformaldehyde and permeabilized using 0.1% 
saponin. pDC were stained for intracellular expression of IL-27p28 (BioLegend, San Diego, CA) 
and IL-12p35 (R&D Systems, Minneapolis, MN) and T cells stained for expression of Foxp3. 
For analysis of Foxp3 expression following cell surface staining, cells were incubated overnight 
using the Foxp3 Fix/Perm kit (eBioscience). 
 
 
 
Figure 2.1 Flow cytometry gating strategy for PDCA-1+ liver and spleen pDC. 
 
For identification of pDC, cells were stained using antibodies against B220 and CD11c. A, First, a live 
cell gate was made using forward (FSC) versus side (SSC) scatter plot. Cell doublets were excluded using 
(B) FSC-Height (H) versus FSC-Area (A). Analysis of surface molecule expression was analyzed on 
B220+CD11clow cells (C), including the pDC-specific marker, Siglec-H (D). 
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2.6 ELISA 
Cytokine levels in culture supernatants were determined by ELISA using kits from BioLegend 
(IL-2, IL-6, IL-10, IL-12p40, and IFN-γ), and R&D Systems (IL-27p28), respectively, following 
the manufacturers’ instructions. 
2.7 T CELL ISOLATION 
Bulk T cells were purified from spleens and LNs of normal BALB/c mice. Single cell 
suspensions were incubated with an Ab cocktail consisting of anti-CD45R/B220 (RA3-6B2), 
anti-CD16/CD32 (2.4G2), anti-TER-119, anti-I-A/I-E, anti-CD11b, and anti-Ly6G (RB6-8C5) 
obtained from BD Pharmingen. Non-T cells were eliminated from the cell suspension by 
negative selection using Dynabeads (Invitrogen) following the manufacturer’s instructions. 
2.8 MLR 
Unstimulated, CpG B- or IL-27-conditioned pDC (2x104/well) were used as stimulators of 
normal allogeneic BALB/c T cells (2x105/well) in a 3 d MLR using 96-well, round-bottom plates 
at a 1:10, DC:T cell ratio. T cells were labeled with the cell tracer CFSE (Invitrogen) for 
identification and proliferation analysis. At the end of the culture period, supernatants were 
harvested for cytokine quantitative analysis by ELISA, and cells were harvested for flow 
cytometric analysis of T cell proliferation and Foxp3 expression. 
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In separate experiments, freshly-isolated, irradiated (2000 rad) or non-irradiated liver or 
spleen pDC or cDC (5x103 up to 2x104) were used as stimulators of normal, allogeneic C3H T 
cells (2x105) with or without 10 ng/ml CpG B (pDC) or LPS (cDC). On day 4, 1 µCi 3H-
thymidine was added to each well for the final 18 hours of culture. Plates were harvested on day 
5 and radioisotope incorporation was quantified using a scintillation counter. Results are 
presented as mean counts per minute (cpm) from 6 wells per group. 
2.9 RNA ISOLATION AND SEMI-QUANTITATIVE RT-PCR 
Total RNA was extracted using TRIzol (Invitrogen) and then reverse transcribed using the 
iScript cDNA Synthesis kit (Bio-Rad). IL-27p28, Ebi3, IL-12p35, WSX-1, and β-actin DNA 
products were amplified with Fast SYBR Green PCR Master Mix (Applied Biosystems; 
Carlsbad, CA) using an ABI PRISM 7000 Fast Sequence Detection System (Applied 
Biosystems). Relative gene expression was determined by comparing to a standard curve for 
each gene and then normalized to β-actin. Primers used for IL-27p28 were forward: 5′-
ATCTCGATTGCCAGGAGTGA-3′ and reverse: 5′-GTGGTAGCGAGGAAGCAGAGT-3′; 
Ebi3, forward: 5′- ATTGCCACTTACAGGCTCGG-3′ and reverse: 5′- 
AAGCAGGGGGATGCCAGA-3′; IL-12p35, forward: 5′- CTGTGCCTTGGTAGCATCTATG-
3′ and reverse: 5′- GCAGAGTCTCGCCATTATGATTC-3′; WSX-1, forward: 5′- 
CAAGAAGAGGTCCCGTGCTG-3′ and reverse: 5′- TTGAGCCCAGTCCACCACAT-3′; and 
β-actin, forward: 5′-AGAGGGAAATCGTGCGTGAC-3′ and reverse: 5′-
CAATAGTGATGACCTGGCCGT-3′. 
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2.10 WESTERN IMMUNOBLOTTING 
Freshly-isolated liver or spleen PDCA-1+ pDC were washed in PBS and cell pellets lysed using 
Cell Lytic M (Sigma) supplemented with complete Mini EDTA-free protease inhibitor cocktail 
(Roche Applied Science, Indianapolis, IN). Cellular debris was removed by centrifugation at 
13,000 x g. Protein was quantified and 20 μg loaded onto 10% Tris-Glycine gels and separated 
using the XCell SureLock Blot Module (Invitrogen). Gels were transferred to polyvinylidene 
fluoride (PVDF) membranes. Membranes were blotted using primary Abs: Ebi3 (2.5 μg/ml; 
eBioscience) or IL-12/IL-35 p35 (1 μg/ml; R&D Systems) and GAPDH (Novus Biologicals, 
Littleton, CO). Primary Abs were followed by HRP-conjugated secondary Abs (Jackson 
ImmunoResearch Laboratories, West Grove, PA). Protein was visualized using Super Signal 
West Pico ECL kit (Pierce – Thermo Fisher Scientific, Rockford, IL). 
2.11 ORAL TOLERANCE AND DELAYED-TYPE HYPERSENSITIVITY 
The protocols for oral tolerance and delayed-type hypersensitivity (DTH) were adapted from 
Goubier et al [209]. For oral tolerance experiments, 8 d Flt3L-mobilized, B6 wild-type (WT) or 
Ebi3-/- mice were fed 25 mg OVA (Grade II, Sigma) in 200 µl PBS by gavage using 3” 20G 
straight, 2.25mm ball animal feeding needles (Fisher Scientific). Flt3L was administered for 2 d 
after OVA feeding. On day 7 after gavage, mice were immunized with 50 µg OVA in 50 µl 
PBS:Complete Freund’s Adjuvant (CFA) emulsion by s.c. injection at the base of the tail. Mice 
were challenged 7 d after immunization s.c. in the hind footpad with 12.5 mg/ml heat-aggregated 
(HA) OVA (Grade VII, Sigma) in 20 μl PBS. HA-OVA was prepared by incubating OVA in 
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PBS at 80°C for 60 min followed by centrifugation at 1900 g for 10 min [246]. The supernatant 
was removed and HA-OVA resuspended in PBS for injection. PBS alone was injected into the 
opposite hind footpad as a control. Footpad thickness was measured (Figure 2.2) at time 0 prior 
to injection and daily thereafter through 96 h post-challenge using Quick Mini Series 700 digital 
calipers (Mitutoyo). Footpad swelling was calculated as the difference in footpad thickness after 
challenge compared to baseline footpad thickness. 
For DTH experiments, DC were mobilized in B6 WT, Ebi3-/- and B7-H1-/- mice, as 
described above. On day 9 of Flt3L administration, the mice were fed 25 mg OVA (Grade II, 
Sigma) in 200 μl PBS by gavage. After 18 h, the animals were euthanized and liver pDC purified 
as described above. For immunization, pDC (105) were co-injected s.c at the base of the tail with 
day 7, GM-CSF/IL-4-propagated CD11c-purified BMDC [247] at a 1:1 ratio in 50 μl PBS. The 
BMDC were pulsed with 1 mg/ml OVA (Grade VII, Sigma) (BMDC-OVA) for 3-4 h prior to 
injection. Un-pulsed BMDC or BMDC-OVA were injected alone as controls. Mice were 
challenged in the footpad with HA-OVA as described above, 7 d after immunization. Footpad 
swelling was quantified and spleens from recipient mice were harvested after 96 h. Total 
splenocytes (2.5x106/ml) were stimulated with 1 mg/ml OVA (Sigma) for 48 h and culture 
supernatants were collected for quantitative analysis of cytokines by ELISA. 
2.12 ALLO-DTH 
Protocol for Allo-DTH was modified from section 2.11. Liver or spleen pDC or cDC (5x106) 
from B6 mice were administered by s.c. injection at the base of the tail of C3H recipient mice 
(C3H used as recipients to mimic strain combination in liver transplant experiments). After 7 
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days, C3H mice were challenged in the footpad with 1x107 B6 splenocytes. Footpad thickness 
was measured every 24 hours for 3 consecutive days. Spleens were harvested from C3H mice on 
day 4 post-challenge and total splenocytes were restimulated ex vivo with irradiated (2000 rad) 
splenocytes from normal B6 (donor), BALB/c (third party), and C3H (syngeneic) mice at a 1:1 
ratio for 4 days. 1 µCi 3H-Thymidine was added to each well for the final 18 hours of culture. 
Radioisotope incorporation was quantified as described above from 6 wells per group. 
Supernatants were harvested from cultures for determination of cytokine production (IL-2 and 
IFN-γ) by ELISA. 
 
 
Figure 2.2 Quantification of footpad swelling using spring-loaded digital calipers. 
Twenty-four hours after mice were challenged in the footpad with heat-aggregated OVA, swelling was 
quantified using Mitutoyo Series 700 digital calipers. Mice were maintained under inhaled anesthesia 
(isoflurane) and three measurements were taken and then averaged for each foot at each time point. 
Baseline footpad thickness was subtracted from footpad thickness at each time point, and this value was 
used as footpad swelling, and reported in µm. 
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2.13 IN VIVO DEPLETION OF pDC 
For pDC depletion in vivo, mice were administered 250 µg of 120G8 mAb by intraperitoneal 
(i.p.) injection on days -2 and -1 prior to liver transplant. We have shown this to be an acceptable 
and effective method for depleting pDC in vivo (Figure 5.11). 
2.14 LIVER TRANSPLANTATION 
The basic techniques of liver harvesting and orthotopic liver transplantation without hepatic 
artery reconstruction were based on the method described [248] with minor modifications [249]. 
B6 liver grafts were perfused with 1 ml of University of Wisconsin (UW) solution via the portal 
vein, stored in UW solution for 24 hours at 4°C, and were implanted orthotopically into C3H 
recipients by the anastomosis of the suprahepatic vena cava with a running 10-0 suture and by 
the anastomosis of the portal vein and inferior vena cava with the cuff technique. The average 
anhepatic time was 19.8 ± 1.7 min. The bile duct was connected via ligation over the stent. 
2.15 STATISTICS 
Statistical significance was determined by unpaired Student’s ‘t’ test or two-way ANOVA where 
appropriate, using GraphPad Prism version 5.00 for Windows (GraphPad Software; San Diego, 
CA). A value of p ≤ 0.05 was considered significant. All experiments were carried out 
independently for a minimum of 3 times, unless indicated otherwise in the figure legends. 
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3.0  PLASMACYTOID DC REGULATE ALLOIMMUNE RESPONSES VIA B7-H1 
3.1 ABSTRACT 
pDC play important roles in innate immunity and in the regulation of adaptive immune 
responses. There is recent evidence that host pDC play a crucial role in regulation of alloreactive 
T cell responses and the promotion of organ transplant tolerance. We evaluated the contribution 
of the inhibitory molecule B7-H1 to the regulation of alloimmune responses by murine pDC. 
Freshly-isolated, PDCA-1 immunobead-purified splenic pDC or CD11c+ cDC were evaluated by 
flow cytometric analysis of surface marker expression and T cell allostimulatory ability was 
assessed in MLR. Splenic pDC from WT (+/- B7-H1 neutralizing mAb) or B7-H1-/- mice were 
pulsed with donor Ag (cell-free BALB/c splenocyte lysate) and T cell allostimulatory capacity 
was assessed MLR. Freshly-isolated WT or B7-H1-/- pDC pulsed with donor Ag were injected 
(2x106) i.v. into syngeneic recipients and splenic and LN CD4+ T cells were purified 7 days later 
for assay in secondary MLR. T cell proliferation was assessed by 3H-thymidine incorporation. 
pDC expressed low levels of CD40, CD80, CD86, and MHC class II compared to cDC, while 
both subsets expressed significant levels of B7-H1. In MLR, pDC were poor stimulators of 
normal CD4+ T cells compared to cDC via both the direct and indirect pathways. However, mAb 
neutralization of B7-H1 on WT pDC and pDC from B7-H1-/- mice yielded greater T cell 
stimulatory capacity compared to untreated WT controls. T cells from mice given immature, 
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donor Ag-pulsed B7-H1-/- pDC showed enhanced activation and greater proliferation in 
secondary MLR compared to mice given WT pDC and to untreated naïve controls. These results 
demonstrate that B7-H1 is a critical molecule on pDC that contributes to the regulation of 
alloreactive T cell responses via the indirect pathway in vitro and in vivo. These data suggest that 
pDC and B7-H1 may be important therapeutic targets in settings such as autoimmunity and 
transplantation, where immune regulation and tolerance is warranted. 
3.2 INTRODUCTION 
3.2.1 Transplantation tolerance: Cell-based therapies to target chronic allograft rejection 
Continued advances in the field of transplantation (surgical techniques and IS drug therapy) have 
vastly improved the short-term survival of vascularized grafts; however, the development of 
graft arterial disease (GAD) and chronic allograft vasculopathy (CAV) leading to late rejection 
still occurs at high rates [85, 250]. Lack of progress in preventing chronic rejection or limiting 
vascular damage in clinical transplantation and a myriad of complications resulting from 
prolonged use of IS support the development and study of promising cell-based therapies in 
transplantation. Cell-based therapies offer the potential to promote tolerance to donor Ag while 
maintaining intact immune responses against opportunistic bacterial and viral pathogens as well 
as malignancies that transplant patients are normally susceptible to under treatment with global 
IS. 
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3.2.1.1 The pathways of allorecognition 
T cell mediated allograft rejection can be initiated via several pathways of allorecognition 
(Figure 3.1) [251]: direct allorecognition – activation of recipient T cells by donor APC; indirect 
allorecognition – activation of recipient T cells by recipient APC that have acquired, processed, 
and present donor alloAg; and semi-direct allorecognition – recipient T cells are activated by 
intact donor MHC molecules on the surface of recipient APC. The precursor frequency of 
directly versus indirectly alloreactive T cells and the loss over time of donor DC versus the 
continuous re-population of recipient DC led to the belief that donor DC (via the direct pathway) 
were primarily responsible for acute allograft rejection, whereas recipient DC (via the indirect 
pathway) mediated chronic allograft rejection [252]. Since IS drug regimens have made 
significant strides in preventing acute allograft rejection episodes, and the indirect pathway has 
emerged as a major contributor to allograft rejection [253]. Therefore, the indirect pathway of 
allorecognition, and thus, recipient DC, serve as an important target for the development of DC-
based therapies in transplantation. 
3.2.2 pDC and transplantation 
The involvement of pDC and transplantation tolerance is discussed in detail in section 1.5.2.4. 
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Figure 3.1 Pathways of alloantigen presentation. 
Three nonmutually exclusive pathways of allorecognition have been described. (A) In the direct pathway, 
recipient T cells recognize intact allogeneic MHC molecules on the surface of donor APCs. The direct 
pathway is responsible for the large proportion of T cells that have reactivity against alloantigens due to 
cross-reactivity of the T-cell receptor (TCR) with self and foreign MHC molecules. (B) In the indirect 
pathway, recipient APCs trafficking through the allograft phagocytose allogeneic material shed by donor 
cells (mostly peptides derived from allogeneic MHC molecules) and present it to recipient T cells on 
recipient MHC molecules. (C) In the semidirect pathway, recipient APCs acquire intact MHC molecules 
following direct contact with donor APCs and/or through fusion with donor APC-derived exosomes. 
These chimeric recipient APCs stimulate recipient T cells through direct and indirect pathways. From 
Sánchez-Fueyo A and TB Strom. 2011. Gastroenterology. 140:51-64.e2. [254] 
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3.2.3 B7-H1: A co-inhibitory B7 family molecule with important implications for immune 
regulation 
B7-H1 (PD-L1) is a recently-described B7 family molecule which acts as a negative regulator of 
T cell activation [191, 255]. B7-H1 is expressed by a variety of cells and tissues, including DC 
[194]. B7-H1 can deliver an inhibitory signal through PD-1 and CD80 (Figure 3.2) expressed on 
activated T cells (and CD80 on DC/APC), and disruption of B7-H1:PD-1 signaling in various 
models boosts T cell-mediated immunity and reduces disease pathogenesis [256-258]. B7-DC, or 
PD-L2, is another ligand for PD-1 that also has been reported to have regulatory function [259], 
however, its cellular distribution is more limited and it is not expressed on pDC [194]. Although 
B7-H1 is critical for modulating immune responses against pathogens, its expression also plays a 
role in regulating immune reactivity against self Ags. B7-H1 expressed on immune cells and 
non-lymphoid tissue serves to prevent T cell-mediated tissue destruction and contributes to self-
tolerance which regulates autoimmune reactivity [260, 261]. The significance of B7-H1 
expression in maintaining tolerance to self-Ags and ability to downregulate T cell responses 
serves as the basis for investigation into its’ role in the ability of pDC to promote tolerance in 
transplantation. 
3.2.3.1 The role of B7-H1 in transplantation 
Using mice deficient in B7-H1 or PD-1, it has been demonstrated that B7-H1 inhibitory 
signaling is a key factor for allograft survival and tolerance [262, 263]. B7-H1 expressed by non-
lymphoid cells is critical for regulating alloreactive T cells directly within the graft through the 
induction of apoptosis of both CD4+ and CD8+ T cells and through the induction of Treg [264-
266]. In addition, we have reported that high B7-H1 expression relative to CD86 on pDC 
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positively correlates with tolerance in liver transplant patients [193]. Despite these findings, the 
significance of B7-H1 expression for the therapeutic capacity of DC in transplantation has not 
been well documented. 
 
 
 
 
Figure 3.2 B7-1:PD-L1 interaction expands pathways in the B7:CD28 family. 
Recent data demonstrate that PD-L1 and B7-1 productively interact on T cells and can deliver 
bidirectional inhibitory signals. The identification of these co-stimulatory molecules as binding partners 
increases our understanding of the interactions that can occur on T cells and APCs and raises the 
possibility that PD-L1:B7-1 binding may not only deliver signals when ligated, but may also serve to 
segregate binding away from previously identified receptors (PD-1, CD28, CTLA-4). IgV-like regions are 
depicted in blue and IgC-like regions in green, while tyrosine-containing signaling motifs are depicted by 
Ys. From Keir ME, Butte MJ, Freeman GJ, and AH Sharpe. 2007. Annu Rev Immunol. 26:677-704. [194] 
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3.3 MATERIALS AND METHODS 
See chapter 2.0 for full description of materials and methods for experiments described in this 
chapter. 
3.4 RESULTS 
3.4.1 Splenic pDC are phenotypically immature compared to cDC 
DC are important mediators of immune responses in the setting of transplantation, in both 
allograft rejection and alloAg-specific immune tolerance. In section 1.3.2, we described 
tolerogenic cDC, and how they may be manipulated to enhance their tolerogenic potential. The 
requirement for prior conditioning of these cells ex vivo, however, may add significant costs and 
concerns should these methods be considered for translation into a clinical setting. Using cells 
such as pDC that possess potent inherent tolerogenic properties may negate the need for ex vivo 
manipulation and makes the potential use of these cells as a therapeutic in transplantation an 
attractive prospect compared to cDC. 
An important characteristic that influences the ability to DC to induce immunity or 
promote tolerance is their level of expression of Ag-presenting, co-stimulatory, and co-inhibitory 
molecules. We compared the expression of key molecules on unstimulated and stimulated 
PDCA-1+ pDC and CD11c+ cDC from spleens of Flt3L-mobilized B6 mice. As described in 
section 1.4.2, B220+CD11clow pDC uniquely express Siglec-H and PDCA-1 (Figure 3.3), 
whereas CD11c+ cDC do not express either molecule. pDC and cDC express similar levels of 
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MHC class I (Kb), however, compared to cDC, pDC express lower levels of MHC class II (I-Ab), 
CD40, CD80, and CD86 (Figure 3.3). Both DC subsets express B7-H1, although pDC express 
more B7-H1 relative to CD40/CD80/CD86. As discussed in section 1.5.1.2, the balance of co-
inhibitory to co-stimulatory molecules on DC plays an important role in 
 
 
Figure 3.3 Phenotypic characterization of splenic pDC and cDC. 
 
PDCA-1+ pDC and CD11c+ cDC from Flt3L-mobilized B6 mice were cultured for 18 h ± CpG B ODN 
(pDC) or LPS (cDC). Cells were harvested from culture and stained for multi-color flow cytometric 
analysis. Histograms represent surface molecule expression on B220+CD11clow cells (as described in 
section 2.4 and shown in Figure 2.1) for pDC and B220-CD11c+ cells for cDC. Shaded histograms 
indicate isotype control, black line indicates unstimulated cells, and red (pDC) and blue (cDC) lines 
represent stimulated cells. 
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determining their functional ability to control immune responses, either positively or negatively. 
Thus, high expression of B7-H1 relative to co-stimulatory molecule (CD40, CD80, and CD86) 
expression on pDC suggests they may be uniquely designed to regulate immune responses in the 
absence of viral infection and type I IFN. Other key differences between pDC and cDC include 
lack of expression of B7-DC/PD-L2 and B7-H2/ICOSL on pDC, while both molecules are 
expressed, or are induced with LPS, on cDC. 
3.4.2 Splenic pDC exhibit weak T cell allostimulatory capacity compared to cDC 
We have shown previously that BM-derived pDC have weak T cell allostimulatory capacity (T 
cell proliferation, IFN-γ, and IL-2 cytokine production) via the direct pathway [128]. In 
correlation with their comparatively immature surface phenotype, Flt3L-mobilized, B6 splenic 
pDC are also poor stimulators of normal, allogeneic BALB/c T cells, compared to cDC via the 
direct pathway, either unstimulated or stimulated with CpG B ODN (Figure 3.4A). We also 
observed this trend when pDC and cDC were first pulsed with BALB/c cell lysate and incubated 
with syngeneic B6 T cells, for evaluation of T cell proliferative capacity via the indirect pathway 
(Figure 3.4B). These differences were statistically significant, and these results are summarized 
in Table 3.1. Several factors implicate the indirect pathway as a major contributor to chronic 
allograft rejection (section 3.2.1.1) and pDC clearly have a weak ability to stimulate allogeneic T 
cells. Thus, the indirect pathway and pDC will be the focus of the rest of the data presented in 
this chapter. 
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3.4.3 B7-H1 expression by splenic pDC is critical for their ability to regulate T cell 
responses 
Based on the reported ability of B7-H1 to negative regulate immune responses and the 
high expression of B7-H1 relative to CD40/CD80/CD86 on pDC, we tested the effects of 
inhibiting B7-H1 signaling on pDC in MLR. Addition of B7-H1 neutralizing mAb to MLR 
resulted in significantly greater T cell proliferation compared to isotype control Ab (Figure 
3.5A). Since B7-H1 can also be expressed on T cells (Figure 3.2), use of B7-H1 mAb in MLR 
does not specifically target B7-H1 on pDC, thus, we utilized B7-H1-deficient mice for isolation 
of pDC to eliminate potential inhibition of B7-H1 on T cells that may skew our results. B7-H1-/- 
splenic pDC also showed enhanced T cell stimulatory capacity compared to WT pDC (Figure 
3.5B), confirming that B7-H1 on pDC contributes to their weak T cell allostimulatory capacity in 
vitro and is important for their inherent tolerogenicity. 
3.4.4 B7-H1 regulates T cell activation in vivo induced by adoptively transferred splenic 
pDC 
The significant contribution of B7-H1 to the weak ability of splenic pDC to stimulate 
alloreactive T cells in vitro suggests that it may be a critical molecule that regulates pDC 
function in vivo. To test this, we adoptively transferred freshly-isolated WT or B7-H1-/- splenic 
pDC that were pulsed with BALB/c cell-free lysate into syngeneic B6 recipient mice. After 7 
days, T cells were purified from the spleens and LNs of B6 recipients. T cells were restimulated 
via the indirect pathway with B6 BMDC pulsed with cell-free BALB/c lysate, and proliferation 
was determined on day 3 by 3H-thymidine incorporation. Mice that received B7-H1-/- splenic 
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pDC showed significantly greater levels of splenic and LN T cell proliferation upon 
restimulation  compared to mice that received WT pDC and untreated naïve controls (Figure 
3.6A). 
 
 
 
 
Figure 3.4 Splenic pDC exhibit weak T cell allostimulatory capacity compared to cDC. 
 
A, Freshly-isolated, B6 spleen PDCA-1+ pDC or CD11c+ cDC were cultured for 18 h with 1 µg/ml CpG 
B ODN, washed, counted, and cultured in MLR with BALB/c splenic T cells. On day 2, 1 μCi/well 3H-
Thymidine was added for the final 18 h, and proliferation was quantified using a scintillation counter. B, 
B6 spleen pDC or cDC were cultured as described in A and pulsed with cell-free, BALB/c lysate. Cells 
were washed, counted, and cultured for 3 d with B6 T cells. Proliferation was quantified by 3H-thymidine 
incorporation as described in A. Statistical significance is presented in Table 3.1. 
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Table 3.1 Statistical significance for data presented in Figure 3.4. 
 
 
 
 
 
Figure 3.5 Inhibition of B7-H1 increases splenic pDC T cell allostimulatory capacity. 
Freshly-isolated, B6 spleen PDCA-1+ pDC were cultured for 18 h with 1 µg/ml CpG B ODN ± cell-free, 
BALB/c lysate, washed, counted, and cultured in MLR with B6 splenic T cells. On day 2, 1 μCi/well 3H-
Thymidine was added for the final 18 h, and proliferation was quantified using a scintillation counter. A, 
B7-H1 mAb (MIH5) or Rat IgG2b isotype control Ab was added 5 µg/ml for the duration of MLR. B, 
Experiment described in A was repeated with B6 WT pDC and B7-H1-/- pDC. No Abs were added to 
MLR in B. * p ≤ 0.05, *** p ≤ 0.001. 
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Flow cytometric analysis of purified T cells from spleens of recipient mice showed that 
CD4+ T cells from mice that received B7-H1-/- pDC exhibited a greater frequency of 
CD44highCD62Llow activated cells (Figure 3.6B) compared to mice receiving WT pDC and 
untreated naïve controls. Together, these data suggest that B7-H1 is necessary for pDC to 
regulate T cell activation and immune responses in vivo. 
 
 
Figure 3.6 B7-H1 regulates splenic pDC function in vivo. 
 
Freshly-isolated, splenic pDC (2x106) from B6 WT or B7-H1-/- mice were pulsed with cell-free BALB/c 
splenocyte lysate and adoptively transferred into syngeneic B6 recipient mice via tail vein injection. After 
7 d, spleens and LNs were harvested and CD4+ T cells were purified. A, Purified T cells were 
restimulated with B6 BMDC that were pulsed with cell-free BALB/c splenic lysate. 1 µCi/well 3H-
thymidine was added for the final 18 h of culture and proliferation was determined by quantification of 
radioisotope incorporation using a scintillation counter. Results are representative of 3 independent 
experiments. B, Purified splenic T cells were analyzed by multi-color flow cytometry for expression of 
activation markers. * p ≤ 0.05, *** p ≤ 0.001. 
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3.5 DISCUSSION 
The data presented in this chapter show that within the splenic DC compartment, pDC have a 
less mature phenotype and exhibit a significantly reduced ability to stimulate allogeneic T cell 
proliferation compared to cDC. The high expression of B7-H1 compared to CD40/CD80/CD86 
on pDC plays a critical role in this phenomenon, and disruption of B7-H1 signaling by pDC 
significantly enhances their ability to stimulate T cell responses, both in vitro and in vivo. 
The role of DC in transplantation has been studied extensively and clearly identifies them 
as important mediators of allograft rejection through presentation of alloAgs to T cells, via 
multiple pathways of allorecognition (Figure 3.1). The ability to modulate DC function to 
promote tolerance enhanced their potential as a possible cell-based therapeutic in transplantation. 
Although much of the focus has been on cDC, pDC have received attention recently, based on 
their unique immunoregulatory properties in the steady state (see section 1.5). Our lab has 
reported on their therapeutic capacity in experimental cardiac transplantation models in mice, 
and we have shown pDC are capable of prolonging allograft survival [128, 267]. Although we 
show their efficacy in vivo in this model, the mechanisms utilized by pDC to promote tolerance 
to alloAgs are not known. 
Our previous studies have described the tolerogenic nature of pDC precursors propagated 
from BM cultures using Flt3L [128], however, the ability of splenic pDC to modulate immune 
responses was not evaluated. Here we show that splenic pDC in the steady state exhibit an 
immature phenotypic profile compared to splenic cDC. This includes drastically reduced 
expression of co-stimulatory molecules and lower expression of MHC class II. Splenic pDC 
maintain high expression of B7-H1 compared to CD40, CD80, and CD86, resulting in a net 
phenotype that favors immune regulation. The relatively immature phenotype of pDC translates 
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to their functional deficiency to induce immune responses against alloAgs. Thus, when splenic 
pDC are cultured in an MLR, they induce significantly less T cell proliferation compared to 
cDC, via both the direct and indirect pathways of allorecognition. The inability of pDC to 
efficiently stimulate T cells relative to cDC is highlighted by the fact that even pDC that have 
been activated with CpG B induce less allogeneic T cell proliferation compared to unstimulated 
cDC. 
High B7-H1 expression relative to CD80 and CD86 on splenic pDC compared to cDC 
stands out as a key characteristic that may regulate splenic pDC allostimulatory capacity, as we 
have described for BM-derived pDC precursors [128]. Blockade of B7-H1 by mAb in MLR 
enhances the T cell stimulatory capacity of splenic pDC via the indirect pathway, leading to 
greater levels of T cell proliferation compared to isotype Ab-treated controls, and confirming that 
B7-H1 expression negatively regulates T cell function. B7-H1 has multiple binding partners 
(PD-1 and CD80) and is expressed on T cells as well as DC (Figure 3.2). Thus, use of mAb 
blockade of B7-H1 in MLR does not definitively identify B7-H1 expression on pDC as the main 
source of inhibitory signals. We utilized B7-H1-deficient mice as a source of splenic pDC, 
thereby eliminating the possibility of B7-H1 signaling on the T cells. B7-H1-/- splenic pDC show 
enhanced T cell stimulatory capacity, which positively links B7-H1 expression to the 
immunoregulatory capacity of splenic pDC. 
As mentioned above, pDC can extend experimental cardiac allograft survival time when 
adoptively transferred into recipients. Despite this, the mechanisms utilized by pDC to regulate 
immune responses in vivo are less clear. B6 CD4+ T cells isolated from the spleens and LNs of 
mice that received adoptive transfer of syngeneic, BALB/c alloAg-pulsed B7-H1-/- splenic pDC 
exhibit significantly greater secondary proliferative responses when restimulated ex vivo via the 
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indirect pathway compared to mice that received B6 WT splenic pDC or naïve, untreated 
controls. Enhanced secondary T cell responses correlate to a more activated phenotype, 
characterized by an elevated frequency of CD62LloCD44hi cells. Taken together with our in vitro 
data, B7-H1 emerges as a key molecule that controls splenic pDC allostimulatory function. 
In summary, of the two main DC subsets in the spleen, pDC have a distinctly different 
phenotype compared to cDC, characterized by low expression of MHC class II and co-
stimulatory molecules, even following TLR stimulation. This translates to their significantly 
weaker ability to stimulate allogeneic T cell proliferation. B7-H1 expression plays a critical role 
in regulating pDC allostimulatory capacity, both in vitro and in vivo, and may be an important 
target to exploit the therapeutic potential of pDC in prolonging experimental cardiac allograft, 
that has been previously observed.  
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4.0  IL-27 AND STAT3-DEPENDENT UPREGULATION OF B7-H1 MEDIATE 
IMMUNE REGULATORY FUNCTIONS OF LIVER PLASMACYTOID DC 
4.1 ABSTRACT 
Plasmacytoid (p) dendritic cells (DC) are highly-specialized APC that, in addition to their well-
recognized role in anti-viral immunity, also regulate immune responses. Liver-resident pDC are 
considerably less immunostimulatory than those from secondary lymphoid tissues and are 
equipped to promote immune tolerance/regulation through various mechanisms. IL-27 is an IL-
12-family cytokine that regulates the function of both APC and T cells, although little is known 
about its role in pDC immunobiology. In this study, we show that mouse liver pDC express 
higher levels of IL-27p28 and EBV-induced protein (Ebi)3 compared to splenic pDC. Both 
populations of pDC express the IL-27Rα/WSX-1; however, only liver pDC significantly 
upregulate expression of the co-inhibitory molecule B7 homolog-1 (B7-H1) in response to IL-27. 
Inhibition of STAT3 activation completely abrogates IL-27-induced upregulation of B7-H1 
expression on liver pDC. Liver pDC treated with IL-27 increase the percentage of CD4+Foxp3+ 
T cells in MLR, which is dependent upon expression of B7-H1. pDC from Ebi3-deficient mice 
lacking functional IL-27, show increased capacity to stimulate allogeneic T cell proliferation and 
IFN-γ production in MLR. Liver but not spleen pDC suppress delayed-type hypersensitivity 
responses to OVA, an effect that is lost with Ebi3-/- and B7-H1-/- liver pDC compared to WT 
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liver pDC. These data suggest that IL-27 signaling in pDC promotes their immunoregulatory 
function and that IL-27 produced by pDC contributes to their capacity to regulate immune 
responses in vitro and in vivo. 
4.2  INTRODUCTION 
4.2.1 The liver: A unique immunologic organ 
The liver is a unique immunologic organ (Figure 4.1) with inherent characteristics that promote 
immune tolerance [60, 268]. Constant exposure to gut-derived products via the portal venous 
blood conditions the liver microenvironment to suppress unwanted inflammatory responses to 
harmless or inert Ags, such as proteins from food or derived from commensal bacteria [60]. The 
liver contains a diversity of cells with Ag-presenting capacity, including liver sinusoidal 
endothelial cells, Kupffer cells or liver-resident macrophages, hepatic stellate cells, and DC. The 
distribution of these APC within the liver sinusoids leads to specialized functional interplay with 
one another and with NK cells, T cells, and hepatocytes, and helps shape this unique 
microenvironment [60]. 
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Figure 4.1 Anatomy, function, and location of liver and liver-resident APCs. 
 
 
A, The metabolic functions of the liver and the flow of products through the portal vein, hepatic artery, 
inferior vena cava and common bile duct. B, General microanatomy of the liver, showing the location of 
central veins and portal tracts, as well as the direction of blood flow. C, Anatomical location of hepatic 
antigen-presenting cells (APCs) and the factors that regulate their function. Branches of the hepatic artery 
merge with sinusoidal vessels carrying blood from the portal vein in the liver, resulting in a mixed arterio-
venous perfusion of the liver with low oxygen tension. Owing to extensive branching of portal vessels 
into liver sinusoids, and the accompanying increase in cumulative vessel diameter, the hepatic 
microcirculation is characterized by low pressure and slow, sometimes irregular, blood flow. Together 
with the narrow diameter of hepatic sinusoids, this facilitates the interaction of circulating leukocytes with 
hepatic sinusoidal cell populations. The hepatic sinusoids are lined by a population of microvascular liver 
sinusoidal endothelial cells (LSECs) that separate hepatocytes and stellate cells (all of which function as 
APCs) from leukocytes circulating through the liver in the blood. Fenestrations in the LSEC lining allow 
the passive exchange of molecules between the space of Dissé and the blood, as well as direct contact of 
lymphocyte filopodia with hepatocyte microvilli. The liver interstitium is highly enriched in cells of the 
innate immune system (such as antigen-presenting dendritic cells, Kupffer cells, natural killer (NK) cells 
and NKT cells (not shown)) and in T cells, which participate in adaptive immune responses. Mediators 
produced by both parenchymal and non-parenchymal cells, including interleukin-10 (IL-10), transforming 
growth factor-β (TGFβ), arginase and prostaglandin E2 (PGE2), regulate immune function within the 
liver. From Thomson AW and PA Knolle. 2010. Nat Rev Immunol. 10:753-766. [60] 
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4.2.2 pDC hold significant immunoregulatory potential 
DC are BM-derived, professional APC that are the most potent activators of T cell-mediated 
immune responses, constituting a critical link between innate and adaptive immunity (section 
1.2). The main subsets in the mouse are cDC (CD11c+CD11b+NK1.1-) and pDC (CD11b-
CD11clowB220+CD8α-). Steady-state pDC express PDCA-1/BST-2/CD317 [147], and the 
endocytic receptor Siglec-H [151] (see section 1.4.2 for full description of pDC). They express 
high levels of endosomal TLR 7, 8 and 9 that sense single-stranded viral RNA (ssRNA; TLR7 
and 8) and unmethylated, CpG-rich viral and bacterial ssDNA (TLR9) [173].  pDC are the 
primary type-I IFN producers in response to viral infection [140, 173, 269]. They are weaker T 
cell stimulators than cDC, and can promote T cell hyporesponsiveness and Treg function [128, 
197, 270]. Consequently, pDC have been linked to the development of tolerance in various 
experimental models and disease states [240]. 
Liver pDC (Figure 4.2) express low levels of MHC class II and co-stimulatory molecules 
(CD40, CD80, and CD86) compared to their counterparts in secondary lymphoid tissues, such as 
the spleen [73, 271]. They also express comparatively high levels of the immunoregulatory 
cytokine IL-10 and B7-H1 (PD-L1) [69, 72], which are known to negatively regulate immune 
responses [96, 272-274]. Despite the implications of these findings for the function of liver pDC, 
the molecular mechanisms that regulate liver pDC function and the expression of 
immunoregulatory molecules by these cells remain underexplored. 
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4.2.3 IL-27 is an emerging cytokine with immunoregulatory function 
IL-27 is a heterodimeric, IL-12-family cytokine (Figure 4.3) comprised of the p40-like molecule 
EBV-induced protein (Ebi)3 and the p35-like molecule p28 [275, 276]. It is produced by APC, 
including macrophages and DC, and signals through the heterodimeric IL-27R that consists of T 
cell cytokine receptor (TCCR)/WSX-1 and the shared gp130 chains [277]. Signaling through the 
IL-27R activates STAT 1, 3, 4, and 5, where STAT1 and STAT3 appear to be the primary 
downstream targets, especially in T cells [278]. Activation of STAT1 by IL-27 has been shown 
to drive Th cell responses toward a Th1/IFN-γ-producing phenotype that favors immune 
activation and pathogen clearance [279]. By contrast, there is considerable evidence [244, 280, 
281] that IL-27 plays an important role in the induction of IL-10-producing, Foxp3-, T-regulatory 
1 (Tr1) cells [282]. In support of an immunoregulatory influence on the outcome of T cell 
responses, IL-27 has been found to suppress the development of inflammatory Th17 cells [283, 
284]. 
The IL-27R is expressed widely on hematopoietic cells and plays distinct roles in their 
function, depending on the cell type on which it is expressed. Mouse splenic CD11c+ DC lacking 
the IL-27Rα/WSX-1 exhibit prolonged upregulation of activation markers and enhanced T cell 
stimulatory capacity following LPS stimulation [285], suggesting that IL-27 exerts 
immunoregulatory effects on DC. In addition, exposure of human monocyte-derived DC to IL-27 
decreases their T cell stimulatory capacity in a B7-H1-dependent manner [286]. It was reported 
recently that mouse splenic pDC express Ebi3 and that it is upregulated following TLR ligation 
[287]. 
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Figure 4.2 Functional biology of liver plasmacytoid DCs. 
 
Unlike conventional myeloid dendritic cells (DCs), plasmacytoid DCs (pDCs) are characterized by their 
ability to secrete type I interferons (IFNs) in response to microbial stimuli that ligate Toll-like receptors 
(TLRs) (such as CpG-containing DNA or lipopolysaccharide (LPS)) or nucleotide-binding 
oligomerization domain (NOD) receptors (such as muramyl dipeptide (MDP)). In vivo exposure of liver 
pDCs to the NOD2 ligand MDP upregulates expression of IFN regulatory factor 4 (IRF4), a negative 
regulator of TLR signaling, and impairs the ability of pDCs to secrete pro-inflammatory cytokines in 
response to TLR ligands and their capacity to induce T cell proliferation and IFNα production. These 
MDP-stimulated liver pDCs have increased cell surface B7-H1 expression, the absence of which (for 
example, on B7-H1-deficient liver pDCs) reverses the inhibitory effect of MDP on liver pDC function. 
The ability of liver pDCs to rapidly delete oral antigen-specific T cells is consistent with the liver as a site 
of CD4+ and CD8+T cell apoptosis. The mechanisms by which liver pDCs may regulate T cell responses 
include the expression of B7-H1, modulation of Notch ligand expression (which promotes T helper 2 
(TH2) cell differentiation), production of interleukin-10 (IL-10) (which promotes regulatory T (Treg) cell 
differentiation) and T cell apoptosis. PD1, programmed cell death 1; TNF, tumor necrosis factor. From 
Thomson AW and PA Knolle. 2010. Nat Rev Immunol. 10:753-766. [60] 
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Moreover, pDC exposed to exogenous TGF-β increase IL-27 production [245] and cDC cultured 
with T cells that constitutively express TGF-β acquire a “plasmacytoid-like” phenotype and 
increase production of IL-27 [244]. TGF-β is an important cytokine in the biology of the liver, 
and its ability to induce IL-27 production by DC suggests a novel mechanism that may 
contribute to the inherent tolerogenicity of the liver. 
 
 
 
Figure 4.3 The interleukin-6 and interleukin-12 family of cytokines and their receptors. 
 
Interleukin-6 (IL-6) is a monomeric cytokine that forms a symmetrical complex with gp130 (glycoprotein 
130) and the IL-6 receptor -chain (IL-6R), and this complex is required for the propagation of 
intracellular signals. IL-12 is a covalently linked heterodimer composed of a light chain (IL-12p35) and a 
heavy chain (IL-12p40). The IL-12 receptor comprises IL-12R1 and IL-12R2, both of which have 
homology to gp130. The IL-12p40 component of IL-12 can also dimerize with IL-23p19 to form IL-23. 
The receptor for this heterodimer is formed by the association of IL-12R1 and IL-23R. The last member 
of this family of cytokines is IL-27, which is composed of EBI3 (Epstein–Barr-virus-induced molecule 3) 
and IL-27p28. IL-27 binds a receptor composed of gp130 and WSX1. The evolutionary relationship 
between these cytokines is shown by the homology of IL-12p35, IL-23p19 and IL-27p28 to other single-
chain cytokines such as IL-6, whereas IL-12p40 and EBI3 more closely resemble the extracellular 
domains of members of the haematopoietic cytokine-receptor family, such as IL-6R. This similarity 
indicates that these heterodimeric cytokines are derived from an early precursor of the IL-6 family and 
from a chain of its receptor. From CA Hunter. 2005. Nat Rev Immunol. 5:521-531. [288] 
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4.2.4 IL-27 and immune regulation in the liver 
As mentioned above, TGF-β, which can be present at relatively high levels within the liver 
microenvironment, induces IL-27 production by DC. Thus, the IL-27/IL-27R axis could play a 
significant regulatory role in hepatic immunobiology. In support of this possibility, IL-27 
produced by liver cDC induces effector T cell hyporesponsiveness and expands CD4+Foxp3+ 
Treg [289]. Moreover, in different models of infection and inflammation, it was demonstrated 
that mice lacking the IL-27R exhibited severe liver pathology [290, 291] and necrosis [292]. 
Despite these important findings, studies linking IL-27, pDC and the liver immunobiology have 
not been reported. 
4.2.5 Liver pDC suppress unwanted immune responses in vivo 
Oral tolerance is a phenomenon whereby feeding of Ag induces Ag-specific hyporesponsiveness 
upon subsequent exposure to the same Ag. It has been shown that induction of oral tolerance is 
dependent on liver and portal vein blood flow [293]. DC play an important role in oral tolerance 
through the capture and presentation of orally administered Ag, and various immunologic sites 
have been implicated in this process [50, 51, 294]. Liver pDC are reported as the key DC subset 
that mediates oral tolerance and that can also suppress Ag-specific delayed-type hypersensitivity 
(DTH) responses [209, 295]. Systemic depletion of PDCA-1+ pDC blunts the effects of Ag 
feeding in oral tolerance, and adoptive transfer of PDCA-1+ liver pDC from OVA-fed mice at the 
time and site of immunization with OVA-pulsed DC suppresses Ag-specific DTH responses 
upon rechallenge [209]. Additionally, IL-27 production is elevated in mesenteric LN DC 
(CD11c+CD11b+ and CD11c+CD11b-) from OVA-fed mice [296]. These data indicate a 
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regulatory role for liver pDC in promoting Ag-specific tolerance and suggest that upregulation of 
IL-27 may contribute to this phenomenon. To date, however, there are no reports that link IL-27, 
liver pDC, and Ag-specific immune regulation. 
4.3 MATERIALS AND METHODS 
See chapter 2.0 for full description of materials and methods for experiments described in this 
chapter. 
4.4 RESULTS 
4.4.1 Liver pDC phenotype and cytokine profile correlates with weak T cell 
allostimulatory ability 
Due to their overall paucity in normal liver, we used Flt3L to expand liver DC [65, 66, 71, 271, 
297, 298], in particular pDC. We found that freshly-isolated, PDCA-1-immunobead-purified 
liver pDC from B6 mice exhibited an immature phenotype, characterized by low cell surface 
expression of MHC II/I-Ab and the co-stimulatory molecules CD40, CD80, and CD86 (Figure 
4.4A). The level of expression of these molecules was generally lower than on pDC isolated 
similarly and concomitantly from the spleen, even following overnight stimulation with the 
TLR9 ligand CpG B ODN (Figure 4.4A). By contrast, liver pDC exhibited higher levels of the 
co-inhibitory molecule B7-H1 compared with similarly-isolated splenic pDC. The ratio of co- 
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Figure 4.4 Liver and spleen pDC differ in phenotype and function. 
A, B6 pDC were mobilized in vivo using Flt3L and enriched from total liver non-parenchymal cells or 
splenocytes as described in the Materials and Methods. PDCA-1-purified pDC were cultured in the 
absence or presence of 1 μg/ml CpG B ODN for 18 h, collected and analyzed by 5-color flow cytometry. 
Surface molecule expression was analyzed on B220+CD11clow cells. Isotypes are represented by the gray-
filled histograms, unstimulated cells (thin line), and CpG B-stimulated (bold line). Data are representative 
of 6 independent experiments; B, The relative mean fluorescence intensities (MFI) [Sample MFI – 
Isotype MFI] for B7-H1 was divided by the MFI for CD86 to generate the B7-H1:CD86 ratio. Data were 
averaged from 4 independent experiments; C, Culture supernatants from cells analyzed in A were 
harvested and cytokines quantified by ELISA. Data represent 3 independent experiments; D, Liver or 
spleen pDC were cultured with CFSE-labeled, allogeneic BALB/c T cells for 3 d. Cultures were 
harvested and proliferation quantified by flow cytometry. Data represent 5 independent experiments,                         
* p < 0.05, ** p< 0.01, ***p < 0.001. 
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inhibitory to co-stimulatory molecules expressed on the surface of APC can strongly influence 
the functional outcome of their interaction with T cells and subsequent immune reactivity [299]. 
We found that liver pDC expressed a significantly higher B7-H1:CD86 ratio relative to splenic 
pDC, both in the steady-state and following TLR9 stimulation (Figure 4.4B). 
The immature cell surface phenotype of liver pDC was associated with lower pro-
inflammatory (IL-6 and IL-12p40) and higher anti-inflammatory (IL-10) cytokine  production 
compared to splenic pDC, either in the absence of or following CpG stimulation (Figure 4.4C). 
Moreover, liver pDC were inferior in their ability to stimulate allogeneic CD4+ or CD8+ T cell 
proliferation compared to pDC from the spleen in 3 d CFSE MLR (Figure 4.4D). These data are 
consistent with observations we have reported previously regarding the phenotype and function 
of murine liver pDC before and after stimulation with LPS in vitro [72], or with CpG B or the 
NOD2 ligand muramyl dipeptide (MDP) in vivo [69]. 
4.4.2 IL-27p28 and the IL-27R/WSX-1 are expressed at comparatively high levels by liver 
pDC 
IL-27 is a recently identified IL-12-family member comprised of the p40-like molecule Ebi3 and 
the p35-like molecule p28 [288]. Early reports on the impact of IL-27 on T cells [279] suggested 
that IL-27 was important for driving Th1-mediated immune responses. It was reported 
subsequently that IL-27 signaling could drive the induction of IL-10-producing, Foxp3- Tr1 cells, 
as well as inhibit the induction of Foxp3+ Treg and IL-17-producing Th17 cells [244, 280, 300-
302]. Interestingly, the p28 subunit alone possesses immune regulatory function. Thus, it was 
shown recently [303] that IL-27p28 can act as an antagonist of gp130-mediated signaling, 
indicating a unique role for this molecule independently of Ebi3. Although it is known that IL-27 
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is produced by APC (primarily activated macrophages but also DC [275, 304]), less is 
understood about the biology of IL-27 in relation to DC function compared to T cells. 
Semi-quantitative RT-PCR analysis of freshly-isolated PDCA-1+ pDC shows similar levels 
of IL-27p28 and Ebi3 mRNA transcripts in liver and spleen pDC (Figure 4.5A). Interestingly, 
Western blot analysis revealed greater levels of Ebi3 protein in liver compared to spleen pDC 
(Figure 4.5B), and intracellular flow cytometry (Figure 4.5C) and quantification in culture 
supernatants by ELISA (Figure 4.5D) revealed greater IL-27p28 levels in liver pDC, suggesting 
possible post-transcriptional differences between pDC in these organs. It was reported previously 
that cDC from the liver produce more IL-27 compared to spleen cDC [289]. We did observe this 
phenomenon; however, we detected greater levels of IL-27p28 production by pDC compared to 
cDC from the liver and spleen, especially following activation (Figure 4.5D). Since Ebi3 is a 
shared component of both IL-27 and IL-35, an additional regulatory cytokine [305], we also 
tested IL-12p35 levels in these cells. We observed lower IL-12p35 mRNA transcripts (Figure 
4.5A) by RT-PCR and protein expression by Western blot (Figure 4.5B) and flow analysis 
(Figure 4.5C) in liver pDC compared to spleen, suggesting IL-35 is not contributing to the 
known immune regulatory function of liver pDC. 
IL-27 signals through the heterodimeric receptor TCCR/WSX-1 and the gp130 subunit, 
which is a shared component in the IL-6R sub-family [277]. In addition to T cells, IL-27R/WSX-
1 is expressed on other hematopoietic cells, including DC, at high levels in the resting state 
[277]. Semi-quantitative RT-PCR (Figure 4.6A) and flow cytometric analysis (Figure 4.6B) 
showed that WSX-1 was expressed at significantly higher levels on liver pDC compared to 
splenic pDC. Together, these data suggest pDC not only produce IL-27, but have the capacity to 
respond to it as well. 
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Figure 4.5 Liver pDC produce comparatively high IL-27p28 but low  IL-12p35. 
A, RNA was purified from freshly-isolated liver or spleen PDCA-1-purified pDC as described in 
Materials and Methods. RNA was reverse transcribed into cDNA and semi-quantitative PCR was 
performed. mRNA transcript levels of IL-27p28, Ebi3, and IL-12p35 were calculated relative to β-actin 
and data are presented as arbitrary units (AU). B, Total protein was extracted from freshly-isolated liver 
or spleen PDCA-1+ pDC as described in Materials and Methods and Western blot performed. The 
membranes were probed for Ebi3 or IL-12p35 and then stripped and reprobed for GAPDH. C, pDC were 
cultured for 18 h and Golgi Plug protein transport inhibitor was added for the final 5 h of culture. Cell 
surface proteins were stained and cells were fixed and permeabilized prior to intracellular staining for IL-
27p28 or IL-12p35. Values indicate percent positive cells and relative MFI compared to isotype controls 
(gray-filled histograms). Percentage of IL-27p28 or IL-12p35 positive cells and MFI were averaged from 
5 and 4 independent experiments, respectively; D, Liver and spleen pDC and cDC were cultured in the 
absence or presence of 1 μg/ml CpG B ODN or LPS for 18 h. Cell culture supernatants were collected 
and IL-27p28 quantified by ELISA. The change in scale from “Untreated” to “+ CpG B” eliminates 
visibility of error bars for liver pDC. Data represent 3 independent experiments, * p < 0.05, ** p < 0.01, 
*** p < 0.001. 
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Figure 4.6 pDC express the IL-27Rα/WSX-1. 
A, WSX-1 mRNA was determined by semi-quantitative RT-PCR for liver and spleen pDC and WSX-1 
gene expression relative to β-actin was calculated. Data are expressed as AU; B, Liver and spleen pDC 
were stained for expression of IL-27Rα/WSX-1 and analyzed by flow cytometry. Values indicate percent 
positive cells and relative MFI compared to isotype controls (gray-filled histograms). Percentage of 
WSX-1 positive cells and MFI were averaged from 3 independent experiments, * p < 0.05, ** p < 0.01. 
4.4.3 IL-27 augments B7-H1 expression on liver pDC 
Previous studies on mouse [285] and human monocyte-derived DC [286] suggested that IL-27 
can downregulate DC function. The high expression of WSX-1 we observed on pDC (Figure 4.6) 
suggests they have the capacity to respond to IL-27 in the steady-state. Therefore, we cultured 
liver and spleen pDC overnight in the presence of IL-27. After 18 h, cells were harvested and 
their phenotype examined by flow cytometry. We found that liver pDC significantly upregulated 
cell surface expression of B7-H1 but concomitantly downregulated expression of CD86, whereas 
there was no significant change in surface molecule expression of corresponding splenic pDC 
(Figure 4.7A and Figure A.1). As a result of increased B7-H1 and decreased CD86 expression, 
there was a significant increase in the B7-H1:CD86 ratio in IL-27-conditioned liver pDC 
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compared to untreated control liver pDC, which displayed high baseline expression of B7-H1 
(Figure 4.4A) and a high B7-H1:CD86 ratio (Figure 4.4B). Interestingly, at a lower 
concentration of IL-27 (10 ng/ml), there was less of an increase in B7-H1 MFI by splenic pDC, 
but a similar response by liver pDC compared to the higher concentration of IL-27 (25 ng/ml). 
Despite upregulation of B7-H1, intracellular flow cytometric analysis and ELISA showed that 
conditioning in IL-27 did not alter production of IL-6, IL-10, IL-12p70 or IFN-α by liver or 
spleen pDC (data not shown). 
pDC also produce IL-6 and IL-10, which are two cytokines abundant in the liver. Therefore, 
we tested whether exposure of pDC to these cytokines would also upregulate B7-H1 as was 
observed following exposure to IL-27. As shown in Figure 4.7B, only IL-27 significantly 
upregulated the expression of B7-H1 on liver pDC. Subsequent analysis revealed that pDC 
expressed low levels of the IL-6Rα and IL-10Rα (Figure 4.7C), especially relative to the high 
expression of WSX-1 (Figure 4.6 and Figure 4.7C). These data suggest a unique role for IL-27 
and WSX-1 in the regulatory function of liver pDC. 
4.4.4 STAT3 regulates IL-27-mediated upregulation of B7-H1 on liver pDC 
It has been reported that STAT3 nuclear activity is greater in the liver than in other organs 
[306]. As a result, a higher basal level of STAT3 activation contributes to the inherent 
immaturity of liver DC. IL-27R/WSX-1 signaling in T cells has shown that STAT3 is a 
significant downstream signaling molecule that regulates the effects of IL-27 [280, 307]. 
Moreover, there is recent evidence that B7-H1 is upregulated on tumor cells through STAT3 
activation [308]. Based on the observations that activated STAT3, B7-H1 and IL-27 are elevated  
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Figure 4.7 IL-27 augments B7-H1 expression on liver pDC. 
A, PDCA-1-purified liver or spleen pDC were cultured for 18 h in the presence of 10 or 25 ng/ml IL-27. 
Cells were harvested, stained, and the expression of B7-H1 and CD86 examined by flow cytometry. 
Results are presented as fold change in B7-H1 MFI on IL-27-conditioned cells compared with untreated 
cells (set to 1.0); B, Liver pDC were cultured with 25 ng/ml IL-27, IL-6, or IL-10 for 18 h and B7-H1 
expression was analyzed. Results represent fold change in B7-H1 MFI; C, Surface expression of the IL-
6Rα, IL-10Rα and WSX-1/IL-27Rα were analyzed on liver and spleen pDC. Data represent percent 
positive cells, D, Experiments in A were repeated in the absence or presence of increasing concentrations 
of a STAT3 inhibitor (STAT3 Inhibitor VII). Data represent 4 independent experiments; E, Percent 
change in B7-H1 expression in the presence of the STAT3 inhibitor compared to untreated cells was 
calculated and averaged from 4 independent experiments; F, Experiments in D and E were repeated with 
a second STAT3 inhibitor JSI-124/Cucurbitacin at the indicated concentrations and compared to STAT3 
Inhibitor VII. Results represent percent change in B7-H1 MFI in the presence of the STAT3 inhibitors 
and are an average of two independent experiments, * p < 0.05, ** p < 0.01, *** p < 0.001. 
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in the liver in the steady state, we postulated that STAT3 might be involved in upregulation of 
B7-H1 by IL-27 on liver pDC. To test this, liver and spleen pDC were cultured overnight in the 
presence of IL-27 and a highly selective STAT3 inhibitor at increasing concentrations. We 
observed a concentration-dependent decrease in B7-H1 expression following STAT3 inhibition 
(Figure 4.7D and Figure 4.7E) in both liver and spleen pDC. Additionally, we found that 
inhibition of STAT3 reduced IL-27-induced upregulation of B7-H1 on liver pDC (Figure 4.7D) 
back to or below baseline levels. To confirm this was indeed a STAT3-dependent effect, we 
tested a second STAT3-specific inhibitor, JSI-124/Cucurbitacin, and obtained similar results 
(Figure 4.7F). 
4.4.5 IL-27-conditioned liver pDC increase percentage of CD4+Foxp3+ T cells which is 
dependent on B7-H1 
Next we tested whether there were any functional consequences, in addition to the phenotypic 
changes observed in pDC, following their exposure to exogenous IL-27. pDC conditioned 
overnight in IL-27 were washed then cultured in MLR with CFSE-labeled, allogeneic BALB/c 
splenic T cells for 3 d. Cultures were harvested and stained for flow cytometric analysis of T cell 
proliferation by CFSE dilution. IL-27-conditioned liver pDC showed minimal differences in 
CD4+ T cell allostimulatory capacity compared to untreated cells (Figure 4.8A). However, 
further analysis of the proliferating CD4+ T cells (cells gated in Figure 4.8A) revealed an 
increased percentage of Foxp3+ cells in cultures stimulated with IL-27-conditioned liver, but not 
spleen pDC (Figure 4.8B). When the percent change in Foxp3 expression in CD4+ T cells 
cultured with IL-27-conditioned pDC relative to untreated pDC was calculated, we found a 
marked difference in the ability of IL-27-conditioned liver and spleen pDC to influence Foxp3 
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expression (Figure 4.8C): thus, liver pDC favored a 30% increase and spleen pDC favored a 
modest decrease in Foxp3 expression. We next tested if this increase in CD4+Foxp3+ T cells was 
due to the upregulation of B7-H1 by IL-27. When WT or B7-H1-/- liver pDC were conditioned in 
IL-27 and then cultured in MLR, we observed that the frequency of CD4+Foxp3+ T cells was 
significantly reduced in cultures with B7-H1-/- liver pDC (Figure 4.8D), suggesting a critical link 
between IL-27 and B7-H1 expression by liver pDC, and Foxp3+ Treg. The increase in the 
proportion of Foxp3+ cells was restricted to proliferating cells, as we did not observe any 
differences in MLR between untreated and IL-27-conditioned liver or spleen pDC in the non-
dividing CD4+ (CFSEhi) population (Figure 4.8E). 
4.4.6 Ebi3-/- mice develop oral tolerance to OVA 
Recent data implicate liver pDC as critical mediators that promote the induction of oral tolerance 
[209], although specific mechanisms were not reported. Shiokawa and colleagues reported that 
IL-27 is upregulated in gut DC following Ag feeding [296], and Tong et al reported exacerbated 
DTH responses in Ebi3-/- mice [309]. Based on our data implicating IL-27 in the inherent 
tolerogenic function of liver pDC, we sought to determine if Ebi3-/- mice could develop oral 
tolerance to the model Ag OVA, and if they failed to do so, could adoptive transfer of WT liver 
pDC that produce IL-27 rescue this phenotype. 
Mobilization of DC in vivo using Flt3L enhances the development of oral tolerance [51], 
therefore, we fed OVA (or PBS as a control) to B6 WT or Ebi3-/- mice by gavage on day 8 of 
Flt3L treatment, and continued Flt3L for 2 days after gavage. Seven days after Ag feeding, all 
mice were immunized s.c. at the base of the tail with OVA in a PBS:CFA emulsion. Another  
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Figure 4.8 IL-27-conditioned liver pDC increase CD4+Foxp3+ T cells in MLR. 
A, Freshly-isolated liver or spleen PDCA-1+ pDC were cultured for 18 h with 25 ng/ml IL-27, washed, 
counted, and cultured in MLR with CFSE-labeled BALB/c splenic T cells. After 3 d, cells were harvested 
and stained for analysis of CD4+ T cell proliferation (A) and expression of Foxp3 (B) by flow cytometry. 
Data represents 3 independent experiments for both A and B; C, The percent change in Foxp3 expression 
in proliferating CD4+ T cells (cells gated in A) in cultures with IL-27-conditioned liver or spleen pDC 
compared to untreated pDC was calculated and average across 3 independent experiments; D, WT or B7-
H1-/- liver pDC were cultured with IL-27 for 18 h and subsequently cultured with BALB/c T cells. 
Intracellular expression of Foxp3 was analyzed by flow cytometry after 3 d MLR and results were 
averaged across 3 independent experiments; E, Foxp3 expression was quantified in non-dividing CD4+ 
cells (CD4+ CFSEhi cells) from experiments shown in A, and averaged across 3 independent experiments,                
* p < 0.05. 
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seven days after immunization, all mice were challenged with heat-aggregated OVA (HA-OVA) 
in the hind footpad and footpad swelling measured at 24-96 h. PBS was injected into the 
opposite footpad as a control. 
As has been shown previously, Flt3L-mobilized B6 WT mice develop oral tolerance to 
OVA (Figure 4.9A and Figure 4.9B) and show significantly less footpad swelling upon challenge 
compared to PBS-fed controls. To our surprise, Ebi3-/- mice also developed oral tolerance 
(Figure 4.9B), with no significant difference in footpad swelling at any of the time points we 
evaluated. These data suggest that IL-27 is dispensable for the development of oral tolerance, 
and we could not proceed with this model to test the functional relevance of liver pDC-derived 
IL-27 in vivo. To simplify our experiment, we adopted only the DTH portion of the oral 
tolerance model, which also would allow us to more directly test the tolerogenic function of liver 
pDC and IL-27 in vivo. 
 
 
Figure 4.9 Ebi3-/- develop oral tolerance. 
DC were mobilized in B6 WT (A and B) or Ebi3-/- (B) mice for 10 d. On day 8 of Flt3L treatment, mice 
were gavaged with 25 mg OVA or PBS as a control. Seven days later, all mice were immunized with 50 
µg OVA in a PBS:CFA emulsion. On day 14, all mice were challenged in the footpad with 12.5 mg HA-
OVA and footpad swelling measured at 24-96 h, * p < 0.05, ** p < 0.01, *** p < 0.001. 
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4.4.7 IL-27 produced by pDC impairs their T cell allostimulatory capacity 
Before testing the tolerogenic function of IL-27 and liver pDC in vivo, we wanted to evaluate the 
contribution of IL-27 to the function of pDC in vitro. Utilizing Ebi3-/- mice that lack functional 
IL-27, liver and spleen pDC were purified and stimulated with CpG B and phenotypic analysis of 
WT and Ebi3-/- pDC was performed. These studies revealed few differences in the expression of 
key cell surface molecules (Figure A.2). Although not statistically significant, Ebi3-/- liver and 
spleen pDC showed a trend towards lower B7-H1 and WSX-1 expression following CpG B 
stimulation. Ebi3-/- spleen pDC showed slightly reduced CD86 MFI, but a significantly greater 
percentage of MHC class II/I-Ab+ cells following overnight exposure to CpG B. We did not 
observe a change in WSX-1 expression on WT pDC following exposure to exogenous IL-27 
(data not shown), however, pDC from Ebi3-/- mice did express a slightly, but not statistically 
significant lower level of WSX-1 (Figure A.2), which suggested that IL-27 signaling through 
WSX-1 may partially upregulate the receptor in an autocrine manner. 
 To determine if lack of functional IL-27 had an impact on pDC-stimulated allogeneic T 
cell responses, WT or Ebi3-/- pDC were cultured in MLR with CFSE-labeled BALB/c T cells for 
3 days. T cell proliferation was quantified by flow cytometry and IFN-γ production in culture 
supernatants was analyzed by ELISA. Analyses of MLR cultures showed that Ebi3-/- liver and 
spleen pDC induced more CD4+ T cell proliferation compared to WT pDC, when either 
untreated or following overnight stimulation with CpG B (Figure 4.10A). No significant 
differences in CD8+ T cell proliferation were observed (data not shown). Increased CD4+ T cell 
proliferation correlated with higher levels of IFN-γ in culture supernatants, (Figure 4.10B), 
suggesting that IL-27 produced by pDC regulates their T cell stimulatory capacity. When T cells 
were stimulated in the absence of pDC (anti-CD3/anti-CD28 Ab stimulation), IL-27 did not 
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suppress T cell proliferation or promote Foxp3 expression (Figure A.3). These data suggest that 
the elevated T cell stimulatory capacity of Ebi3-/- pDC, and therefore, the regulatory effect of IL-
27, is due to a pre-conditioning of the pDC by IL-27 in vivo and not a direct effect on the T cells. 
4.4.8 IL-27 and B7-H1 mediate liver pDC ability to suppress DTH responses 
Despite their ability to promote anti-viral immunity, pDC also exert tolerogenic effects and 
modulate immune responses [240]. Specifically, systemic depletion of PDCA-1+ cells blunts the 
development of oral tolerance, and adoptive transfer of liver pDC from Ag-fed mice at the site 
and time of immunization suppresses Ag-specific DTH responses [209]. Thus, we hypothesized 
that IL-27 expressed by liver pDC might mediate their capacity to suppress DTH to fed Ag. 
 
 
 
Figure 4.10 Ebi3-/- pDC exhibit greater CD4+ T cell stimulatory capacity compared to WT. 
A, Unstimulated or CpG B ODN-stimulated (18 h) PDCA-1+ WT and Ebi3-/- liver or spleen pDC were 
cultured with allogeneic, CFSE-labeled BALB/c T cells. After 3 d MLR, cells were harvested and stained 
for analysis of T cell proliferation by CFSE dilution; B, IFN-γ was quantified in supernatants from 
cultures in 6A by ELISA, * p < 0.05, ** p < 0.01, *** p < 0.001. 
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First, we tested whether suppression of DTH responses was limited to pDC from the liver, 
and confirmed their ability to do this in an Ag-dependent manner. Liver and spleen PDCA-1+ 
pDC were isolated from mice fed OVA by gavage, or PBS as a control. pDC were co-injected 
s.c. at the base of the tail at a 1:1 ratio with syngeneic BM-derived DC (BMDC) that were pulsed 
with OVA (BMDC-OVA). BMDC or BMDC-OVA were injected alone as controls. After seven 
days, mice were challenged in the footpad with HA-OVA and footpad swelling was quantified. 
Compared to BMDC alone, BMDC-OVA induced a significant level of footpad swelling upon 
challenge with HA-OVA at 24 h (Figure 4.11A). Liver pDC from OVA-fed mice, but not from 
PBS-fed controls significantly suppressed footpad swelling when co-injected at the same site and 
time of immunization with BMDC-OVA (Figure 4.11A). Spleen pDC from OVA-fed mice or 
PBS-fed controls failed to suppress DTH responses (Figure 4.11A). Together, these results 
confirm that suppression of DTH responses is specific to liver pDC and is dependent upon Ag 
acquired though feeding. 
To test whether IL-27 was required for the regulatory effect of liver pDC in the model of 
DTH to OVA, WT or Ebi3-/- liver pDC from mice fed OVA were co-injected with BMDC-OVA 
as described above. Mice were challenged in the footpad with HA-OVA and footpad swelling 
quantified at 24 h post-challenge. Liver pDC from Ebi3-/- mice failed to suppress DTH responses 
compared to WT liver pDC (Figure 4.11B). When splenocytes from these mice were 
restimulated ex vivo with OVA, we detected greater levels of IFN-γ in cultures supernatants from 
mice that received Ebi3-/- liver pDC compared to WT liver pDC (Figure 4.11C). To highlight the 
significance of these findings and the importance of IL-27 in the functional biology of liver pDC, 
we compared these results to liver pDC from mice lacking B7-H1, which is a known potent 
regulator of immune responses. 
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Figure 4.11 WT, but not Ebi3-/- or B7-H1-/- liver pDC suppress DTH responses to OVA. 
B6 mice were immunized with B6 BMDC-OVA ± liver or spleen pDC from PBS-fed control or OVA-fed 
mice (A), or WT, Ebi3-/- or B7-H1-/- liver pDC from OVA-fed mice (B) by s.c. injection at the base of the 
tail. 7 d later, mice were challenged in the footpad with HA-OVA and footpad swelling measured at 24 h; 
C, Total splenocytes from challenged mice were cultured for 48 h with 1 mg/ml OVA and supernatants 
harvested for quantification of IFNγ by ELISA, * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
B7-H1-/- liver pDC also failed to suppress DTH responses compared to WT pDC. Footpad 
swelling (Figure 4.11B) and splenocyte production of IFN-γ (Figure 4.11C) were at a similar 
level as observed for mice receiving Ebi3-/- liver pDC, suggesting IL-27 and B7-H1 play a 
significant role in the immunoregulatory capacity of liver pDC. 
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4.5 DISCUSSION 
The data presented in this chapter show that pDC express IL-27 as well as the IL-27R/WSX-1. 
Liver pDC express higher levels of both proteins compared to pDC from the spleen, and also 
exhibit a unique capacity to respond to IL-27 through upregulation of the co-inhibitory molecule 
B7-H1. We found STAT3 to be critical for this phenomenon, as its pharmacologic inhibition 
completely abrogated the effect of IL-27. A functional consequence of liver pDC conditioning by 
IL-27 was an ability to increase the incidence of CD4+Foxp3+ cells in allogeneic MLR. IL-27 
contributes to the ability of pDC to regulate T cell responses in vitro, and our data also identify 
IL-27 and B7-H1 as critical molecules utilized by liver pDC to suppress DTH responses to OVA 
in vivo. 
Although studied typically for their potent anti-viral function through production of type I 
IFNs [140, 269], pDC have garnered significant attention for their immunosuppressive function, 
and multiple mechanisms of immune regulation and tolerance by pDC have been studied by our 
lab and others [240]. Important features of pDC that shape their immunoregulatory function 
include their low level of Ag-presenting (MHC class II) and co-stimulatory molecules (CD80 
and CD86) and unique regulation of MHC class II expression [31] which lead to poor T cell 
stimulatory function compared to cDC [128]. As we show here, pDC residing in the liver 
microenvironment show even lower expression of MHC class II and co-stimulatory molecules 
(CD40, CD80, and CD86) compared to pDC isolated concomitantly from the spleen. Both pDC 
populations exhibit high baseline expression of the co-regulator B7-H1, however levels on liver 
pDC are greater than on spleen pDC. Liver-resident APC, including pDC, are continuously 
exposed to bacterial degradation products (e.g., endotoxin) via the portal blood [306] leading to 
constant stimulation of TLRs and other pattern recognition receptors (PRRs), which may 
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contribute to their comparatively high baseline expression of B7-H1.  We have demonstrated 
previously that an elevated B7-H1:CD86 ratio on pDC is positively correlated with successful 
weaning of IS drug therapy or operational tolerance in liver transplant patients, suggesting that 
this may be an important characteristic associated with the tolerogenic capacity of pDC [310]. 
Analysis of the ratio of B7-H1 to CD86 MFI on liver and spleen pDC in this study clearly 
highlights the regulatory potential of liver pDC, based on their significantly elevated ratio of co-
inhibitory to co-stimulatory molecule expression compared to pDC from the spleen. 
In addition to their more immature phenotype compared with splenic pDC, liver pDC 
produce lower levels of the pro-inflammatory cytokines, IL-6, IL-12p40 and IL-12p70 [69], but 
greater levels of the immunoregulatory cytokine IL-10 in the steady state, or after stimulation 
with LPS [72] or CpG B. Similar to the fact that pDC are poor T cell allostimulators relative to 
cDC, liver pDC are comparatively weak stimulators compared with pDC from the spleen, of both 
CD4+ and CD8+ T cells. 
Previous studies have identified IL-27 to play a role in the functional biology of DC, in 
addition to its known effects on T cell polarization and function. Liver cDC, mobilized through 
hydrodynamic injection of plasmids encoding GM-CSF, showed elevated levels of IL-27p28 
compared to their counterparts in the spleen [289]. We observed a similar difference between 
liver and spleen cDC following LPS stimulation, but also found that pDC have a greater capacity 
for IL-27p28 production relative to cDC, and we detected higher levels of both p28 and Ebi3 in 
liver pDC compared to spleen pDC. Our detection of the p28 subunit in the culture supernatants 
of liver pDC (and intracellularly by flow cytometry) lends support to the tolerogenic potential of 
liver pDC, as p28 has been suggested to exert immunoregulatory function when secreted 
independently of Ebi3 [303, 311]. In support of our findings on IL-27, PDCA-1+ splenic pDC 
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exposed to exogenous TGF-β (which is produced by multiple cell types in the liver, [60]) show 
elevated IL-27 and decreased IL-6 production compared to untreated controls [245], suggesting 
that the immunoregulatory molecules found within the normal liver microenvironment (i.e. TGF-
β) may contribute to elevated IL-27 production by liver pDC. pDC also express p35, which can 
heterodimerize with Ebi3 to form the regulatory cytokine IL-35. However, low expression of p35 
by liver pDC, which we have shown exhibit greater regulatory phenotype and function compared 
to pDC in the spleen, suggests that p35 and Ebi3 may not be forming functional IL-35 in these 
cells. The higher expression of p35 by spleen pDC, which have greater immunostimulatory 
capacity compared to liver pDC, supports this observation. The presence of two distinct 
populations of IL-12p35+ cells from the spleen is an interesting observation and may indicate 
phenotypically and functionally different subpopulations. The IL-12p35hi spleen pDC may be 
responsible for the greater levels of IL-12p70 we have reported previously in these cells [72]. 
IL-27 binds to the heterodimeric IL-27R comprised of IL-27Rα/WSX-1/TCCR and gp130 
[277]. Although gp130 is a shared subunit for multiple cytokines, WSX-1 is specific to IL-27 
and is expressed by pDC, suggesting they have the capacity to respond to IL-27. Indeed, in the 
presence of exogenous IL-27, liver but not spleen pDC upregulated B7-H1 but not CD86 
expression. Consequently, IL-27-conditioned liver pDC have a significantly elevated B7-
H1:CD86 ratio compared to untreated cells. Furthermore, liver pDC are more sensitive to lower 
concentrations of IL-27, highlighting the significance of higher WSX-1 expression on these cells. 
Studies on T cells have revealed important roles for STAT1 and STAT3 signaling in mediating 
downstream effects of IL-27 [279, 280]. Wölfle et al [312] recently showed that STAT3 directly 
binds the B7-H1 (PD-L1) promoter and drives its expression. When we used a soluble inhibitor 
to block STAT3 activation in vitro, upregulation of B7-H1 by IL-27 was abrogated. 
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Additionally, B7-H1 levels on liver and spleen pDC in the absence of IL-27 also decreased, 
confirming that STAT3 promotes B7-H1 expression on pDC. IL-6 and IL-10 also signal through 
STAT3, however, the increase in B7-H1 expression we observed was unique to IL-27. 
Subsequent analysis showed low expression of both the IL-6R and IL-10R. These data not only 
suggest that these cytokine receptors may not critically influence pDC function, but also 
highlight the significance of high expression of the IL-27Rα/WSX-1 in the functional biology of 
these cells. Interestingly, we noted that exposure to IL-27 did not alter IFN-α, IL-6, IL-10, or IL-
12p70 production by pDC, despite a report that IL-27 blunts TNF-α and IL-12p40 production in 
activated peritoneal macrophages via a STAT3-dependent mechanism [313]. 
Liver pDC [209, 295] and IL-27 [296] have been implicated in the development of oral 
tolerance, providing a model to test the importance of these two molecules together in vivo. We 
hypothesized that Ebi3-/- would fail to develop oral tolerance, thus allowing us to rescue this 
phenotype using WT liver pDC which produced functional IL-27. Using Flt3L-mobilized mice 
which were shown previously to exhibit enhanced development of oral tolerance [51], we 
observed that Ebi3-/- mice were still able to develop oral tolerance to OVA. Based on these data, 
we would not be able to directly test the contribution of IL-27 to the tolerogenic function of liver 
pDC. We simplified our approach by using only the DTH portion of the protocol, as described 
previously [209], which would directly allow us to test the immunoregulatory function of IL-27 
produced by liver pDC. 
We first needed to evaluate the functional immunobiology of Ebi3-/- liver pDC compared to 
WT. In studies using WSX-1-deficient mice, Yoshida et al [285] showed that, in the absence of 
IL-27 signaling, spleen cDC exhibited enhanced T cell stimulatory capacity in MLR, suggesting 
that IL-27 negatively regulates DC function. In agreement with these data, human monocyte-
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derived DC exposed to exogenous IL-27 at high levels show a reduction in T cell stimulatory 
capacity, which is dependent on B7-H1 expression [286]. Although we did not observe any 
significant phenotypic differences in Ebi3-/- pDC compared to WT pDC, a trend towards lower 
B7-H1 and WSX-1 expression and a greater incidence of Ebi3-/- MHC class II (I-Ab)+ cells 
supports the existence of an autocrine feedback loop by IL-27 in pDC. When IL-27-conditioned 
pDC were cultured with allogeneic T cells, there was a greater proportion of proliferating CD4+ 
T cells expressing the Treg transcription factor Foxp3 in cultures with liver, but not spleen pDC. 
This effect was lost when IL-27-conditioned B7-H1-/- liver pDC were used as stimulators. 
Supporting a regulatory role for IL-27 in pDC immune function, Ebi3-/- pDC showed an 
enhanced ability to stimulate allogeneic T cell proliferation and subsequent IFN-γ production. 
The addition of IL-27 to these cultures did not suppress T cell proliferation to levels observed 
with WT pDC, suggesting that the regulatory effect of IL-27 in WT pDC, that is absent in Ebi3-/- 
pDC, is due to a pre-conditioning by IL-27 in vivo, and not a direct effect of IL-27 produced by 
pDC on T cells. Overall, IL-27 may influence liver pDC regulatory function by upregulating B7-
H1 expression and enhancing their ability to promote Foxp3+ Treg while reducing their T cell 
allostimulatory capacity. 
In a series of DTH and contact hypersensitivity (CHS) experiments, Goubier et al [209] 
showed recently that liver pDC (CD11c+CD11b-NK1.1-) accounted for the suppressive capacity 
of total CD11c+ hepatic DC. Liver pDC suppressed both Ag-specific DTH and CHS responses to 
model Ags, whereas they reported spleen pDC failed to inhibit immune reactivity in their CHS 
model. Furthermore, systemic depletion of pDC blunted the induction of oral tolerance to OVA. 
Our data provide strong evidence that liver but not spleen pDC suppress DTH responses to OVA 
in an Ag-dependent manner. Moreover, we have identified novel mechanisms contributing to this 
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phenomenon. IL-27, as evidenced using Ebi3-/- liver pDC, and B7-H1, as evidenced using B7-
H1-/- liver pDC, are critical for the ability of liver pDC to significantly suppress DTH responses. 
These data suggest that liver pDC can sufficiently acquire fed Ag and limit priming of the 
immune response during the immunization phase. Since pDC can inhibit cDC activation [160], it 
remains to be seen in this model whether pDC: suppress BMDC-OVA directly to inhibit the 
priming phase; migrate to the LNs to inhibit T cell activation; or both. The capacity of liver pDC 
to partially but not significantly suppress DTH responses in an Ag-independent manner (PBS-
Liver pDC, Figure 4.11A) in addition to their significant suppression in an Ag-dependent fashion 
(Figure 4.11B and 4.11C) suggests they are able to actively regulate immunity through multiple 
mechanisms.  
In summary, our studies show that IL-27 plays a critical regulatory role in the functional 
biology of liver pDC. First, IL-27 promotes cell surface expression of B7-H1 in liver pDC 
which, in turn, increases the incidence of CD4+ T cells expressing Foxp3. The effects of IL-27 
on liver compared to spleen pDC suggest the potential for unique signaling molecules 
downstream of the IL-27R in these cells, which may be critical in regulating their tolerogenic 
capacity. Second, IL-27 is critical for liver pDC ability to regulate immune responses in vitro and 
in vivo, with the potential for regulation of cDC, T cells, or both. Together, these results suggest 
that IL-27 and liver pDC may be important targets or tools for therapeutic intervention to limit 
immune reactivity or promote tolerance. 
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5.0  DONOR pDC CONTRIBUTE TO THE SPONTANEOUS ACCEPTANCE OF 
FULLY MHC-MISMATCHED MURINE LIVER ALLOGRAFTS 
5.1 ABSTRACT 
Liver pDC possess significant capacity to regulate immune responses. In experimental liver 
transplantation in rodents, liver allografts are accepted spontaneously from fully MHC-
mismatched donors without the use of therapeutic intervention. We sought to determine how 
donor liver pDC, acting as “passenger leukocytes” during transplantation, may promote 
spontaneous acceptance of murine liver allografts relative to other DC subsets. Freshly-isolated, 
B6 liver and spleen immunobead-purified PDCA-1+ pDC or CD11c+ cDC were cultured in MLR 
with allogeneic, C3H T cells. Proliferation was quantified by 3H-thymidine incorporation, and 
cytokine production in culture supernatants was determined by ELISA. Freshly-isolated B6 liver 
or spleen pDC or cDC were injected s.c. into C3H recipients. After 7 days, C3H mice were 
challenged in the footpad with B6 splenocytes and footpad swelling was quantified. Splenocytes 
from C3H recipient mice were restimulated ex vivo with donor (B6), third-party (BALB/c) or 
syngeneic (C3H) splenocytes, and proliferation and cytokine production were determined. Liver 
pDC exhibited weak allogeneic T cell stimulatory capacity in vitro and poor ability to prime the 
alloresponse in vivo compared to all other DC groups tested. Donor livers from mice depleted of 
pDC were not spontaneously accepted and did not induce tolerance in our model. In conclusion, 
 98 
liver pDC exhibit a weak ability to stimulate alloresponses in vitro and in vivo compared to other 
DC subsets, however, the mechanisms they utilize to promote spontaneous acceptance of liver 
allografts remain to be defined. 
5.2 INTRODUCTION 
5.2.1 Hepatic DC and immune regulation 
Our group has played a significant role in the characterization of liver DC (pDC and cDC; Figure 
5.1 and Figure 5.2) and their ability to regulate immune responses and promote tolerance [65, 66, 
68, 314]. To examine their tolerogenic ability, many studies from our lab and others have 
compared liver DC function to that of lymphoid (spleen) DC [69-73], which have been well 
characterized and are known to be potent inducers of immunity. Interestingly, liver DC possess a 
phenotype and function that is similar to what has been described for tolerogenic DC (see section 
1.3.2). Thus, compared to spleen DC, liver DC exhibit: reduced expression of co-stimulatory 
(CD40, CD80, CD86) and Ag-presenting (MHC class II) molecules, and comparatively high 
expression of co-inhibitory molecules (B7-H1); reduced production of IL-12 and elevated 
production of IL-10; enhanced ability to induce/promote Foxp3+ Treg; and an enhanced ability to 
induce effector T cell apoptosis and/or hyporesponsiveness. The composition of DC subsets 
(Figure 5.3) within the liver is also skewed compared to lymphoid tissue [73], with an elevated 
proportion of pDC and CD11c+NK1.1+ natural killer (NK) DC that exhibit APC as well as 
natural killer cell functions [315]. NKDC have only been described in the mouse, and a human 
equivalent has not yet been identified. 
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5.2.1.1 Molecular regulation of hepatic DC function 
As discussed in section 4.2.1 and described in Figure 4.1, the liver is continuously exposed to 
bacterial degradation products (e.g. TLR ligands) via the portal venous blood coming from the 
gut, resulting in a constant state of TLR stimulation. To prevent unwanted activation and 
maturation, DC in the liver have a unique molecular profile that maintains them in a relatively 
immature state. Due to the constant basal level of TLR stimulation (e.g., TLR stimulation with 
LPS), liver DC show impaired activation (reduced upregulation of co-stimulatory molecules and 
production of pro- inflammatory cytokines) compared to DC from lymphoid tissues when 
stimulated ex vivo/in vitro with LPS, a phenomenon termed endotoxin tolerance [64]. 
 
 
Figure 5.1 Liver DC morphologies and surface marker expression. 
DC were isolated from murine liver as described [46]. Using immunoscanning electron microscopy 
(SEM), two liver DC populations have distinct morphologies that correlate with specific surface marker 
expression (B220 vs. CD11b when examined using backscatter analysis). These results indicate that the 
liver harbors both plasmacytoid (p) and conventional myeloid (m) DC (SEM black bars = 1 lm, 
backscatter white bars = 100 nm). From: Thomson AW, Geller DA, Gandhi C, Murase N, Demetris AJ, 
and D Beer-Stolz. 2011. Immunol Res. 50:221-227. [316] 
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Liver DC also exhibit cross-tolerance, where LPS-stimulated DC show impaired responses upon 
subsequent exposure to other TLR ligands such as CpG [65]. These data suggest regulation 
within intracellular signaling pathways in liver DC that differs from DC in other tissues that 
ultimately leads to the maintenance of their immature status. 
 
 
 
Figure 5.2 Mouse liver DC visualized using in situ multiplex Qdot immunostaining. 
 
Investigation into the molecular mechanisms regulating liver DC maturation has produced 
several important observations (Figure 5.3) [60, 64]. Gut-derived bacterial degradation products 
present in the portal venous blood induce IL-6 production in liver DC leading to increased 
phosphorylation of STAT3 [306]. This leads to elevated expression of IL-1R-activated kinase 
(IRAK)-M, which is a known negative regulator of TLR signaling. Expanding on this study, we 
have reported recently [71] that the intracellular adaptor protein DAP12 plays a critical role in 
regulating liver DC maturation. DAP12 expression is enhanced in liver DC compared to other 
organs (spleen, lung, and kidney), and stimulation of liver DC with physiological concentrations 
of LPS (100 -1000 pg/ml; [317]) further increases DAP12 expression [71]. 
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Figure 5.3 Representation of DC subsets in the liver and spleen. 
Schematic representation of the proportion of DC subsets in the liver and spleen based on multi-color 
flow cytometric analysis. Adapted from: Pillarisetty VG, Shah AB, Miller G, Bleier JI, and RP DeMatteo. 
2004. J Immunol. 172:1009-1017. [73] 
 
 
In support of the findings mentioned above, DAP12 expression also promotes STAT3 
activation and subsequent IRAK-M expression. Silencing of DAP12 using small-interfering 
(si)RNA technology results in: increased production of the pro-inflammatory cytokines TNF-α, 
IL-6, and IL-12p70 and decreased production of IL-10; elevated expression of CD80 and CD86; 
enhanced T cell stimulatory capacity in vitro and in vivo; and decreased expression of IRAK-M. 
Moreover, as discussed in section 1.4.2.2, DAP12 associates with Siglec-H in pDC and plays an 
important role in their immunologic function. These important findings identify critical targets 
for future therapeutic intervention to target DC activation and promote or modulate their immune 
stimulatory capacity. 
 102 
5.2.2 Liver allotransplantation 
The most striking evidence supporting the tolerogenic nature of the liver is that in many rodent 
(mouse and rat) MHC-mismatched strain combinations [248, 318] and in human patients [319], 
liver allografts are spontaneously accepted (operationally tolerant) without the use of IS drug 
treatment, or in the clinical setting, without the continued use of IS. Moreover, in human 
transplantation, liver allografts that are not spontaneously accepted typically require reduced 
levels of IS compared to other solid organ allografts, and patients are often successfully weaned 
from IS drug therapy while maintaining allograft function [320-322]. 
5.2.2.1 Migration of donor hepatic DC following liver allotransplantation 
“Passenger leukocytes” are cells resident in the donor organ that migrate to lymphoid tissues of 
the recipient following transplantation. This is evidenced by the fact that donor progenitor cells 
have been found in recipient BM following liver allotransplantation, and DC can be propagated 
from these BM cultures [323]. Moreover, following transplantation, inflammation and 
ischemia/reperfusion (I/R) injury can cause DC activation and maturation [324], leading to 
upregulation of CCR7 and subsequent migration to recipient secondary lymphoid tissues [325, 
326]. In the setting of transplantation where hepatic lymph vessels are severed and inflammation 
is present, liver DC can migrate to spleen and celiac LNs [327] or portal tract-associated 
lymphoid tissue (PALT) [325], which may be an important step towards inducing immune 
tolerance in this model [328]. Collectively, these data suggest that trafficking of donor liver DC 
to lymphoid compartments in the recipient provides them with the opportunity for interactions 
with recipient cells that may contribute to the induction of tolerance to the transplanted liver.  
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Figure 5.4 Mechanisms downmodulating the responsiveness of liver myeloid DC to LPS. 
Recent evidence indicates that gut-derived commensal bacterial products, typified by lipopolysaccharide 
(LPS), inhibit mouse liver dendritic cell (DC) maturation by stimulating production of hepatic 
interleukin-6 (IL-6). In turn, this stimulates signal transducer and activator of transcription 3 (STAT3) 
activity downstream of the IL-6 receptor (IL-6R) in liver DCs. Hepatic DCs in normal, wild-type mice are 
phenotypically and functionally less mature than DCs from IL-6-deficient or STAT3-inhibited IL-6-
sufficient mice. Moreover, IL-6-induced STAT3 signaling seems to increase the expression of IL-1 
receptor-activating kinase M (IRAK-M), a negative regulator of Toll-like receptor (TLR) signaling (that 
would otherwise lead to DC maturation), in liver CD11c+ DCs. IL-10 and transforming growth factor-β 
(TGFβ), which are produced by various liver cell populations, signal through STAT3 and SMAD 
proteins, respectively, to repress activation of nuclear factor-κB (NF-κB), thus inhibiting hepatic DC 
maturation. In addition, there is new evidence that the transmembrane adaptor protein DNAX-activating 
protein of 12 kDa (DAP12), which has been implicated in the negative regulation of TLR responses in 
DCs, is expressed at comparatively high levels by liver myeloid DCs and negatively regulates their 
maturation in association with IRAK-M expression. This results in impaired production of the T helper 1 
(TH1) cell-inducing cytokine IL-12, but increased secretion of IL-10. From: Thomson AW and PA 
Knolle. 2010. Nat Rev Immunol. 10:753-766. [60] 
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5.2.2.2 pDC and liver allotransplantation 
In an effort to understand the mechanism surrounding tolerance in liver allotransplantation, 
extensive studies have been performed to identify key biomarkers [319] that are associated with 
spontaneous acceptance/operational tolerance that may be used to identify patients who are 
candidates for weaning from IS, or that may be applied to other solid organ allografts to prevent 
rejection. Our group has observed an elevated ratio of pDC to cDC (Figure 5.4) in the circulation 
of operationally tolerant patients and those undergoing prospective weaning from IS but not 
those on maintenance IS [193] in pediatric liver transplantation. These pDC exhibited a high B7-
H1:CD86 ratio on their surface, and this correlated with an increased frequency of Foxp3+ Treg. 
Moreover, liver cDC are able to induce deleterious Th1 T cell responses that may contribute to 
liver allograft rejection [329], suggesting that pDC, and not cDC, may play a critical role in the 
overall success of liver allografts. To our knowledge, however, a direct role for donor pDC in 
promoting allograft tolerance in liver transplantation has not been evaluated. 
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Figure 5.5 Circulating pDC/mDC ratios in pediatric liver transplant patients. 
Tolerant (TOL) and prospective weaning patients (PW) exhibit higher circulating %precursor 
pDC/%precursor mDC ratios compared with patients on maintenance immunosuppression (MI) and 
controls (N). A, Historical four-color method. B, Direct DC subset staining method; values are expressed 
as percentage of PBMC. Data were generated as depicted in Figure 1. Individual patient or control values, 
arithmetic means, and significances of differences between groups (ascertained as described in the 
Materials and Methods by multiple comparisons using Bonferroni correction) are shown. *P<0.05. C, The 
precursor pDC/precursor mDC1 ratio obtained using the direct DC staining method shows a good 
correlation with the precursor pDC/precursor mDC ratio obtained using the historical four-color staining 
procedure. From: Tokita D, Mazariegos GV, Zahorchak AF, Chien N, Abe M, Raimondi G, and AW 
Thomson. 2008. Transplantation. 85:369-377. [193] 
5.3 MATERIALS AND METHODS 
See chapter 2.0 for full description of materials and methods for experiments described in this 
chapter. 
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5.4 RESULTS 
5.4.1 Liver pDC exhibit weak ability to stimulate allogeneic T cell responses in vitro 
Based on our observations that liver pDC exhibit potent immunoregulatory function, we sought 
to determine how they influenced allogeneic T cell responses compared to liver cDC. These two 
populations of cells (Figure 5.1 and Figure 5.2) may play key roles in the spontaneous 
acceptance of murine liver allografts, therefore, their ability to regulate or stimulate allogeneic T 
cells warrants evaluation. These data will help determine if donor liver pDC (or cDC) might 
contribute to the induction of tolerance in liver allograft recipients, based on the outcome of 
recipient T cell responses. 
B6 (donor strain) liver pDC or cDC were cultured with normal, allogeneic C3H (recipient 
strain) T cells, and proliferation was quantified by 3H-thymidine incorporation. Liver pDC 
induced very low levels of allogeneic T cell proliferation compared to liver cDC (Figure 5.6A 
and Figure 5.7A). Moreover, liver pDC were the weakest T cell stimulators compared to liver 
cDC, splenic pDC, and splenic cDC. We observed these results using freshly-isolated, 
unstimulated, irradiated DC (Figure 5.6A), or non-irradiated DC +/- CpG B ODN (pDC) or LPS 
(cDC) (Figure 5.7A). Supernatants harvested from these cultures were assayed for cytokine 
production by ELISA. Liver pDC induced less T cell production of IFN-γ and IL-2 (Figure 5.6B 
and Figure 5.7B) compared to all other DC groups. Interestingly, pDC induce similar levels of 
IL-10 (Figure 5.6B) compared to the other DC groups. Analysis of the ratios of IFN-γ:IL-10 and 
IL-2:IL-10 (Figure 5.6C) shows that liver pDC induce very high levels of IL-10 relative to IFN-γ 
and IL-2. Moreover, when IL-10 levels are divided by the proliferation from Figure 5.6A, liver 
pDC show the greatest ratio, suggesting liver pDC may be inducing IL-10-producing Treg. 
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These data suggest that liver pDC can promote regulatory responses by T cells without inducing 
significant levels of effector T cell activation, and ultimately, liver pDC may be a critical subset 
of donor DC that could promote allograft tolerance in the recipient following liver 
transplantation. 
 
 
 
Figure 5.6 Liver pDC exhibit weak ability to stimulate allogeneic T cell responses. 
Freshly-isolated PDCA-1+ pDC or CD11c+ cDC from livers and spleens of B6 mice were irradiated (2000 
rad) and cultured with allogeneic C3H T cells (CD4+ and CD8+) for 5 days. A, 1 µCi 3H-thymidine was 
added to each well for the final 18 hours of culture. Proliferation was quantified as radioisotope 
incorporation using a liquid scintillation counter and shown as counts per minute (CPM). B, Culture 
supernatant from A was assayed by ELISA for IFN-γ, IL-2, and IL-10. C, The ratios of IL-
10:proliferation, IFN-γ:IL-10 and IL-2:IL-10 were calculated from data in B.  * p ≤ 0.05, ** p ≤ 0.01, *** 
p ≤ 0.001. 
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Figure 5.7 Liver pDC remain weak T cell allostimulators following activation. 
Freshly-isolated PDCA-1+ pDC or CD11c+ cDC from livers and spleens of B6 mice were cultured with 
allogeneic C3H T cells (CD4+ and CD8+) for 5 days in the absence or presence of 10 ng/ml CpG B ODN 
(pDC) or LPs (cDC). A, 1 µCi 3H-thymidine was added to each well for the final 18 hours of culture. 
Proliferation was quantified as radioisotope incorporation using a liquid scintillation counter and shown 
as counts per minute (CPM). B, Culture supernatant from A was assayed by ELISA for IFN-γ and IL-2.   
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
 
5.4.2 Liver pDC fail to prime allogeneic immune responses in vivo 
Due to their weak ability to stimulate allogeneic T cell responses in vitro, we next determined if 
liver pDC could prime donor-specific responses in vivo. B6 liver or spleen pDC or cDC were 
injected s.c. into C3H recipient mice. After 7 days, all mice were challenged in the hind footpad 
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with B6 splenocytes, and footpad swelling was quantified at 24, 48, and 72 hours post-challenge. 
We did not observe any significant differences in levels of footpad swelling between any of the 
groups (Figure 5.8A). Within individual experiments, some of the animals that were immunized 
with liver pDC showed lower levels of footpad swelling relative to the other groups (Figure 
5.8B), however, an average of all animals tested did not reveal significant differences between 
any DC groups (Figure 5.8A). 
 
 
 
Figure 5.8 Use of Allo-DTH to assess DC ability to prime alloresponses in vivo. 
Freshly-isolated PDCA-1+ pDC or CD11c+ cDC (5x106) from livers and spleens of B6 mice were injected 
s.c. into C3H recipients. After 7d, C3H mice were challenged in the footpad with 1x107 B6 splenocytes. 
Footpad swelling was quantified at 24, 48, and 72 h post-challenge. A, Data are an average of 3 mice. B, 
Representative data of 3 independent mice. 
 
 
Despite no significant differences in footpad swelling, we harvested spleens from C3H 
recipient mice at 96 h post-challenge and restimulated them with irradiated B6 (donor), BALB/c 
(third-party), or C3H (syngeneic) splenocytes at a 1:1 ratio for 4 days. Proliferation and cytokine 
production by C3H recipient cells were quantified by 3H-thymidine incorporation and ELISA, 
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respectively. Naïve C3H mice that were not primed with B6 DC showed a weak proliferative 
response (Figure 5.9A) and produced very little IFN-γ (Figure 5.9B) when restimulated with B6 
splenocytes. In correlation with our in vitro data (Figure 5.6 and Figure 5.7), liver pDC did not 
strongly prime the alloresponse in vivo, since C3H that were primed with all other DC groups 
exhibited greater secondary responses (Figure 5.9) compared to mice primed with liver pDC. A 
similar observation was noted for C3H responders restimulated with BALB/c splenocytes, 
suggesting a modest level of T cell activation not specific against B6 alloAgs. The response 
against syngeneic (C3H) splenocytes was minimal, and no significant differences were observed 
between all four DC groups tested.  
 
 
 
Figure 5.9 Liver pDC do not elicit strong alloresponses in vivo. 
Freshly-isolated PDCA-1+ pDC or CD11c+ cDC (5x106) from livers and spleens of B6 mice were injected 
s.c. into C3H recipients. After 7d, C3H mice were challenged in the footpad with 1x107 B6 splenocytes. 
After 96 h, spleens were harvested from C3H recipient mice, and restimulated ex vivo with irradiated 
splenocytes from B6 (donor), BALB/c (third-party), or C3H (syngeneic) mice for 4 d.  A, 1 µCi 3H-
thymidine was added to each well for the final 18 hours of culture and proliferation was determined by 
quantification of radioisotope incorporation using a liquid scintillation counter. B, Culture supernatant 
from A was assayed by ELISA for IFN-γ. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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5.4.3 High expression of ICAM-1 and ICAM-2 on liver pDC may contribute to their 
tolerogenic capacity 
Adhesion molecules play an important role in T cell trafficking and activation. The interaction of 
leukocyte function-associated Ag (LFA)-1 with intracellular adhesion molecule (ICAM)-1 is 
critical for both activation of T cells by APC/DC and for migration of activated T cells into 
inflamed tissues [330]. ICAM-1/LFA-1 interactions have also been associated with the immune 
regulatory function of several cell types, especially within the hepatic microenvironment. 
Hepatocytes are able to induce apoptosis of activated T cells [331] and hepatic stellate cells can 
inhibit T cell function [332]; both of which are dependent on expression of ICAM-1. ICAM-2 
also binds to LFA-1, and although ICAM-1 expression may be more critical for interaction with 
T cells, ICAM-2 also plays a role in mediating T cell responses [333]. 
Based on the weak ability of liver pDC to stimulate allogeneic T cells (Figure 5.6 and 
Figure 5.7), we analyzed ICAM-1 and ICAM-2 expression on pDC. pDC isolated from both the 
liver and spleen showed positive expression of ICAM-1 and ICAM-2 (Figure 5.10). 
Interestingly, liver pDC expressed significantly greater levels of both molecules compared to 
spleen pDC, both before and after stimulation with CpG B. A greater difference in expression 
between liver and spleen pDC was observed for ICAM-2 compared to ICAM-1, however, both 
molecules were expressed at greater levels on liver pDC (Figure 5.10). These data suggest that 
liver pDC may be able to form stronger interactions with T cells compared to spleen pDC, and 
their known regulatory function and inability to adequately stimulate T cell responses suggests 
expression of these molecules may support other functions. 
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Figure 5.10 ICAM-1 and ICAM-2 expression on liver and spleen pDC. 
PDCA-1+ B6 liver or spleen pDC were cultured for 18 h with or without 1 µg/ml CpG B ODN. Cells 
were harvested from culture and stained for analysis of expression of ICAM-1 (CD54) and ICAM-2 
(CD102) by flow cytometry. A, Representative histograms for ICAM-1 and ICAM-2 expression on liver 
and spleen pDC. Isotype control (shaded histogram), unstimulated pDC (thin line), pDC + CpG B (bolded 
line). B, Percent expression and MFI for ICAM-1 and ICAM-2 on pDC were averaged across 4 
independent experiments.  ** p ≤ 0.01, *** p ≤ 0.001. 
 
 
5.4.4 Donor pDC promote long-term survival of fully MHC-mismatched liver allografts 
In solid organ transplantation, the liver is regarded as a tolerogenic organ that typically requires 
less IS to prevent rejection, and can be accepted spontaneously across MHC barriers 
(spontaneous operational tolerance). This phenomenon may be largely dependent upon donor-
derived cells (passenger leukocytes) [323, 327] that are transplanted into the recipient with the 
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allograft and can promote tolerance to alloAgs. Our group has clearly defined a tolerogenic role 
for pDC in the liver, however their role in spontaneous acceptance of liver allografts has not 
been reported. 
We used the monoclonal antibody 120G8 to deplete pDC in vivo from B6 mice (Section 2.13 and 
Figure 5.11). Livers were harvested from pDC-depleted mice and transplanted orthotopically 
into C3H recipients. Graft survival was monitored based on animal survival. In the mouse model 
of B6 to C3H liver allotransplantation, livers are spontaneously accepted and the animals survive 
long-term (Mean survival time [MST] = 95 days) in the absence of therapeutic intervention 
(Figure 5.12) or IS treatment. When livers from pDC-depleted B6 mice were used as donors, 
mean survival time was much shorter (MST = 25 days). These data are the first to directly 
identify donor liver pDC as a critical cell population required for long-term survival and 
spontaneous acceptance of murine liver allografts. 
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Figure 5.11 In vivo depletion of PDCA-1+ pDC. 
B6 mice were administered 120G8 monoclonal antibody i.p. and depletion of pDC was confirmed by 
flow cytometric analysis. Top panel shows representative data and bottom panel shows an average of 3 
mice. Data courtesy of A. Castellaneta. 
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Figure 5.12 Donor liver pDC promote spontaneous acceptance of murine liver allografts. 
Livers from normal (untreated) or pDC (120G8)-depleted B6 mice were transplanted orthotopically into 
C3H recipient mice and survival was monitored. Data are represented graphically (A) as percent survival 
or in tabular form (B) including individual mouse survival times. MST = mean survival time, # represents 
2 mice that were alive and healthy that were sacrificed at day 105 post-transplant for histological analysis. 
 
5.5 DISCUSSION 
The data presented in this chapter clearly identify liver pDC as having a very weak ability to 
stimulate allogeneic immune responses. Their T cell allostimulatory capacity in vitro and ability 
to prime immune responses to alloAgs in vivo is weaker compared to cDC in the liver, and to 
both pDC and cDC from the spleen. Liver pDC exhibit an elevated expression of ICAM-1 and 
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ICAM-2 compared to spleen pDC and their expression may govern interactions with T cells and 
other APC that contributes to their ability to regulate immune responses. The significant 
tolerogenic potential of liver pDC is highlighted by the fact that when pDC are depleted from the 
donor, liver allografts are not spontaneously accepted as observed with normal, WT donor livers. 
 Liver DC have garnered significant attention in recent years for their profound ability to 
regulate immune responses [60]. Recent studies from our lab and others have made significant 
progress in elucidating the mechanisms that regulate their inherent tolerogenic capacity 
compared to DC in lymphoid tissues [65, 69-73, 306]. Thus, DC residing in the liver 
microenvironment are conditioned such that in the steady state and certain pathological 
conditions, their function favors the development of immunological tolerance. 
In chapter 3.0, we present data that show spleen pDC are phenotypically immature and 
possess weaker T cell allostimulatory capacity compared to spleen cDC. In chapter 4.0, our data 
show that liver pDC are more immature and possess weaker T cell allostimulatory compared to 
spleen pDC. Comparison of all four DC subsets in the present chapter identifies liver pDC as the 
being the weakest T cell allostimulators in in vitro MLR assay compared to liver cDC, and 
spleen pDC and cDC. B6 liver pDC induce significantly less proliferation, and IFN-γ and IL-2 
production from C3H T cells. They do however, induce similar levels of IL-10 production, and 
comparison of IFN-γ and IL-2 to IL-10 shows that liver pDC are able to induce high levels of IL-
10, despite failure to promote effector T cell function. Further highlighting these data, analysis of 
the ratio of IL-10 to proliferation shows that liver pDC promote the induction of IL-10 producing 
T cells to a greater degree than any other DC group evaluated here. We showed in Chapter 4.0 
that liver pDC produce high levels of IL-27 which limits their T cell allostimulatory ability, and 
IL-27 is also known to induce IL-10-producing Tr1 Treg [244]. Thus, liver pDC may 
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preferentially induce the generation of IL-10-producing Tr1 Treg over effector T cells through 
production of IL-27. Further investigation into the phenotype of the T cells in these cultures 
could provide additional support for this hypothesis. 
In solid organ transplantation, donor DC or “passenger leukocytes”, are believed to play a 
significant role in rejection as they migrate from the graft to secondary lymphoid tissues in the 
recipient and initiate immune responses against alloAgs via the direct pathway of allorecognition 
[334, 335]. Although they traffic from the allograft to secondary lymphoid tissues, donor liver 
DC persist in the recipient following liver transplantation [248], and their distinct regulatory 
function may play a significant role in spontaneous liver allograft acceptance in experimental 
animal models. In correlation with their weak ability to stimulate allogeneic T cells in vitro, liver 
pDC exhibit a very limited capacity to prime immune responses to alloAgs in vivo. Compared to 
C3H primed with B6 liver cDC, mice primed with liver pDC exhibited weaker secondary 
responses (proliferation and cytokine production) when restimulated ex vivo with B6 alloAgs. 
We did not, however, detect differences between experimental groups in levels of footpad 
swelling following challenge with B6 splenocytes in these mice. This may be due in part, to the 
large number of B6 splenocytes injected in the footpad (1x107). The level of swelling induced by 
the presence of these cells in the footpad may not allow us to observe subtle, yet significant 
differences in the recall response between the groups. In support of this, we typically did not 
observe any differences until nearly 72 hours following footpad challenge for each experiment 
(Figure 5.3B), whereas in the DTH model using OVA, we could detect significant differences 
after only 24 hours when using OVA protein for footpad challenge (Figure 4.10). Repeated 
experiments using fewer cells for footpad challenge may allow for the observation of more subtle 
differences between the groups. Conversely, an increase in the number of DC injected during the 
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immunization/priming phase may also result in a greater initial response during the priming 
phase, thus resulting in a greater degree of footpad swelling upon challenge with splenocytes. 
It was recently reported in human liver transplantation [329], that donor liver cDC are 
capable of stimulating allogeneic Th1 T cell responses in recipients of liver allografts and may 
contribute to liver allograft rejection. Thus, liver pDC, and not cDC, may be a critical cell 
population that can promote spontaneous acceptance of liver allografts in experimental models 
and in the clinical setting. Overall, our data evaluating the ability of liver pDC to prime immune 
responses to alloAgs in vivo suggest that in the setting of liver transplantation, donor liver pDC 
that migrate from the graft into the recipient may not elicit strong responses to alloAgs. 
As mentioned earlier, many mechanisms have been attributed to the tolerogenic capacity 
of liver pDC, including molecular regulation of key immunomodulatory proteins. This results in 
in skewed expression of key molecules, at lower levels (CD40, CD80, CD86, MHC class II, IL-
6, and IL-12) or higher levels (B7-H1 and IL-10) compared to spleen pDC [70]. Interestingly, we 
show that liver pDC also express higher levels of ICAM-1/CD54 and ICAM-2/CD102 compared 
to spleen pDC. These two adhesion molecules are typically thought of as being important for 
activation of T cell responses [330], however a role for them in regulating immune responses has 
also been reported. Hepatic stellate cells are known to inhibit T cell responses, and recent data 
show that elevated expression of ICAM-1 is critical for their ability to restrict T cell activation, 
including regulation of expression of the high affinity IL-2R and production of IL-2 [336]. Thus, 
high ICAM-1 expression on liver pDC may contribute to their weak T cell allostimulatory 
capacity and failure to induce significant amounts of IL-2 production. It is also possible that 
ICAM-1 regulates liver pDC function. ICAM-1/LFA-1 interactions between Foxp3+ Treg and 
DC can downregulate CD80 and CD86 expression on DC and their subsequent ability to activate 
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allogeneic T cell responses [337]. Our data that show liver pDC express low levels of co-
stimulatory molecules CD80 and CD86 (Figure 4.4), and they promote Foxp3+ Treg expression 
(Figure 4.8) suggesting specific interactions between these two cell populations. Consequently, 
the elevated expression of ICAM-1 on liver pDC compared to spleen pDC may be contributing 
to these phenomena.  
More marked than differences in ICAM-1 expression, ICAM-2 is expressed at 
significantly greater levels on liver pDC compared to spleen pDC. Like ICAM-1, ICAM-2 is also 
a ligand for LFA-1, however, it binds at higher affinity to DC-SIGN [338], an Ag uptake 
molecule which is expressed by cDC (see section 1.2.1.1). DC-SIGN downstream signaling 
events can promote DC maturation [339], thus, it remains to be seen if ligation of DC-SIGN on 
cDC by ICAM-2 can inhibit cDC maturation. It was recently shown that pDC are able to inhibit 
cDC maturation via B7-H1 [160], and the ability of pDC to bind to cDC with high affinity via 
ICAM-2/DC-SIGN may facilitate regulation by B7-H1, suggesting an additional mechanism 
through which that pDC might be able to regulate cDC function. 
Their immature and regulatory phenotype, weak ability to prime immune responses to 
alloAgs in vitro and in vivo, and migratory ability of donor DC following liver transplantation 
suggests that liver pDC may be a critical cell population contributing to the spontaneous 
acceptance of fully MHC-mismatched murine liver allografts. In the strain combination of B6 to 
C3H liver transplantation in mice, liver allografts are ‘spontaneously’ accepted with long-term 
graft survival (MST = 95 days) and minimal histological evidence of rejection (at 105 days post-
transplant). Strikingly, when B6 donor mice were depleted of pDC prior to surgery, liver 
allografts were rejected with an MST of 25 days. Based on our in vitro data, this could be caused 
by failure to induce IL-10-producing Tr1 Treg that may be necessary to prevent rejection. 
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In summary, our data represents the first report to directly link donor liver pDC as being 
a critical cell population that long-term allograft survival and tolerance in a mouse model of liver 
allotransplantation. Coupled with their weak ability to prime immune responses to alloAgs, these 
data suggest that as liver pDC migrate from the donor liver into recipient lymphoid tissues, they 
may be interacting with recipient cells to promote tolerance to the transplanted organ. 
Investigation into the mechanisms that are required for pDC to promote tolerance in this model is 
warranted and will be the focus of future studies. We have previously shown that IL-27 and B7-
H1 are two important molecules that regulate the tolerogenic capacity of liver pDC, and B7-H1 
expression has already been defined as an important molecule that regulates cold I/R injury [340] 
following liver transplantation. Thus, these represent two key molecules that may be essential for 
the regulatory role of donor liver pDC in liver transplantation. 
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6.0  SUMMARY 
The concept of cell-based therapies for clinical application to treat disease pathologies has been 
around for a long time. They have been investigated as a means to bolster immune responses 
such as in the case of cancer or chronic infection, as well as to regulate unwanted immune 
reactivity in the case of autoimmunity and transplantation. A leading area of research is focused 
on DC for their ability to promote or modulate these responses in an Ag-specific fashion, leaving 
the remaining immune system intact to function normally. Moreover, pDC have emerged as an 
important cell population with the ability to modulate immune responses in favor of regulation 
and tolerance [240], especially in experimental transplantation models [128, 188, 229]. Recent 
data from the group led by Dr. Suzanne Ildstad [219] have brought tolerogenic pDC to the 
forefront with exciting results utilizing a population of facilitating cells containing pDC 
precursors [218, 341, 342] that promote chimerism and donor-specific tolerance with successful 
withdrawal from immunosuppression in combined kidney and hematopoietic stem cell transplant 
patients. These are important findings that highlight the regulatory capacity of pDC and strongly 
support investigation of pDC as a means for promoting tolerance induction in the clinical setting. 
The data presented herein clearly indicate that pDC exhibit significant capacity to 
modulate immune responses in vitro and in vivo. Moreover, pDC residing in the liver 
microenvironment possess potent immune regulatory function, even more than their counterparts 
in the spleen and compared to cDC. Based on these data and results from clinical studies 
 122 
mentioned above, we conclude that pDC may be a powerful, and more suitable alternative to 
cDC, and should be considered as a potential cell-based therapeutic in disease settings where 
regulation of immune responses is merited. 
6.1 CAVEATS AND FUTURE DIRECTIONS 
One of the major caveats of utilizing pDC as a cell-based therapy to promote tolerogenic 
immune responses is their ability to secrete large amounts of type I IFN (up to 1,000 times more 
than any other cell type). Type I IFN can activate just about every other cell type, which is 
critical for mounting potent anti-viral immune responses and limiting viral replication and the 
spread of infection. This may have detrimental effects for use in transplantation and 
autoimmunity, since TLR activation may prevent induction of transplant tolerance [343], and 
type I IFN can promote cDC and T cell function, exacerbate disease pathologies in many 
autoimmune disorders and may contribute to solid organ allograft rejection. It has been shown, 
however, that even CpG-activated human pDC induce functionally suppressive 
CD4+CD25+Foxp3+ Treg [344], suggesting they are still capable of promoting tolerance 
following activation. Further study into the tolerogenic properties of TLR-activated pDC are 
warranted in this case. 
Our novel data on the functional immunobiology of liver pDC highlight their significant 
capacity for modulating immune responses. Unfortunately, the feasibility of obtaining pDC from 
the liver for use in the clinical setting seems improbable in most scenarios. Therefore, DC 
derived from human PBMC may be conditioned using certain tolerogenic factors found within 
thin the liver microenvironment (e.g., IL-27, TGF-β, PGEs, or IL-10) to enhance their 
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tolerogenicity. TGF-β has been shown to upregulate IL-27 in pDC [245], and IL-27 upregulates 
B7-H1 expression on DC [70, 106], thus providing support for such studies. Fortunately, in the 
case of human pDC, IL-3 can be used as a survival factor and makes their study in vitro easier 
than that of mouse pDC, which do not express the IL-3R and fare poorly in culture for extended 
periods of time. Alternatively, pDC from other tissues that are more readily obtainable (e.g., pre-
pDC present in the BM facilitating population [219]) may present an alternative to the need for 
conditioning ex vivo. 
We have identified pDC as having significant tolerogenic potential compared to cDC, 
and that pDC in the liver are even more tolerogenic than those in the spleen. Our data using the 
DTH model to OVA and our data demonstrating that livers from pDC-depleted donors fail to 
induce tolerance and are rejected in a model where liver allografts are accepted spontaneously in 
the absence of IS intervention support these findings. These studies will serve as the basis for 
future investigation into the mechanisms utilized by donor liver pDC that contribute to 
spontaneous allograft acceptance using our mouse liver transplant model. The observation that 
liver pDC induce very little allogeneic T cell proliferation, IFN-γ and IL-2 production, yet still 
induce relevant amounts of IL-10 production provides strong evidence for mechanistic 
involvement of liver pDC in promoting tolerance in liver allotransplantation. The trafficking and 
migration patterns of donor liver pDC into host lymphoid tissues, interaction with host 
lymphocytes, and characterization of important molecules and signaling pathways, in addition to 
the ones identified here, are also important questions that remain unanswered and warrant further 
investigation. 
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APPENDIX A 
SUPPLEMENTARY DATA 
 
 
Figure A.0.1 Histograms depicting B7-H1 expression on liver pDC in response to IL-27 
Freshly-isolated liver and spleen PDCA-1+ pDC from Flt3L-mobilized, C57BL/6J WT mice were 
cultured in the presence of 25 μg/ml CpG B ODN for 18 h, collected and analyzed by 5-color flow 
cytometry. Surface  expression of B7-H1 was analyzed on B220+CD11clow gated cells as previously 
described in Materials in Methods. Relative MFI of untreated (thin line) and IL-27-conditioned (bold line) 
liver and spleen pDC is shown, along with the fold change in B7-H1 MFI following exposure to IL-27. 
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Figure A.0.2 Ebi3-/- pDC are phenotypically similar to WT pDC 
Freshly-isolated liver and spleen PDCA-1+ pDC from Flt3L-mobilized, WT or Ebi3-/- mice were cultured 
in the presence of 1 μg/ml CpG B ODN for 18 h, collected and analyzed by 5-color flow cytometry. 
Surface protein expression was analyzed on B220+CD11clow gated cells (Figure A1) as previously 
described in section 2.4 of the Materials in Methods. Relative MFI and percent positive cells were 
average from 3 independent experiments, * p < 0.05. 
 
 
Figure A.0.3 Exogenous IL-27 enhances T cell proliferation and reduces Foxp3 expression 
Freshly-isolated liver and spleen PDCA-1+ pDC from Flt3L-mobilized, C57BL/6J WT or Ebi3-/- mice 
were cultured with allogeneic BALB/c splenic T cells in the absence (white bars) or presence of 1 (light 
gray bars) or 10 (dark gray bars) ng/ml IL-27 for 3 d. Cultures were harvested and analyzed by flow 
cytometry for proliferation by CFSE dilution (A) and Foxp3 expression (B). T cells were also stimulated 
with plate-bound anti-CD3 and soluble CD28 (A-B). Results are an average of n =2 independent 
experiments, ** p < 0.01, *** p < 0.001. 
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